385 results on '"Lenglet A"'
Search Results
2. Correction: Early warning for healthcare acquired infections in neonatal care units in a low-resource setting using routinely collected hospital data: The experience from Haiti, 2014-2018.
- Author
-
Annick Lenglet, Omar Contigiani, Cono Ariti, Estivern Evens, Kessianne Charles, Carl-Frédéric Casimir, Rodnie Senat Delva, Colette Badjo, Harriet Roggeveen, Barbara Pawulska, Kate Clezy, Melissa McRae, Heiman Wertheim, and Joost Hopman
- Subjects
Medicine ,Science - Abstract
[This corrects the article DOI: 10.1371/journal.pone.0269385.].
- Published
- 2024
- Full Text
- View/download PDF
3. Multimodal MRI improves diagnostic accuracy and sensitivity to longitudinal change in amyotrophic lateral sclerosis
- Author
-
Pramod Kumar Pisharady, Lynn E. Eberly, Isaac M. Adanyeguh, Georgios Manousakis, Gaurav Guliani, David Walk, and Christophe Lenglet
- Subjects
Medicine - Abstract
Abstract Background Recent advances in MRI acquisitions and image analysis have increased the utility of neuroimaging in understanding disease-related changes. In this work, we aim to demonstrate increased sensitivity to disease progression as well as improved diagnostic accuracy in Amyotrophic lateral sclerosis (ALS) with multimodal MRI of the brain and cervical spinal cord. Methods We acquired diffusion MRI data from the brain and cervical cord, and T1 data from the brain, of 20 participants with ALS and 20 healthy control participants. Ten ALS and 14 control participants, and 11 ALS and 13 control participants were re-scanned at 6-month and 12-month follow-ups respectively. We estimated cross-sectional differences and longitudinal changes in diffusion metrics, cortical thickness, and fixel-based microstructure measures, i.e. fiber density and fiber cross-section. Results We demonstrate improved disease diagnostic accuracy and sensitivity through multimodal analysis of brain and spinal cord metrics. The brain metrics also distinguished lower motor neuron-predominant ALS participants from control participants. Fiber density and cross-section provided the greatest sensitivity to longitudinal change. We demonstrate evidence of progression in a cohort of 11 participants with slowly progressive ALS, including in participants with very slow change in ALSFRS-R. More importantly, we demonstrate that longitudinal change is detectable at a six-month follow-up visit. We also report correlations between ALSFRS-R and the fiber density and cross-section metrics. Conclusions Our findings suggest that multimodal MRI is useful in improving disease diagnosis, and fixel-based measures may serve as potential biomarkers of disease progression in ALS clinical trials.
- Published
- 2023
- Full Text
- View/download PDF
4. Temporomandibular disorders cases with high-impact pain are more likely to experience short-term pain fluctuations
- Author
-
Alberto Herrero Babiloni, Fernando G. Exposto, Connor M. Peck, Bruce R. Lindgren, Marc O. Martel, Christophe Lenglet, David A. Bereiter, Lynn E. Eberly, and Estephan J. Moana-Filho
- Subjects
Medicine ,Science - Abstract
Abstract Temporomandibular disorders (TMD) patients can present clinically significant jaw pain fluctuations which can be debilitating and lead to poor global health. The Graded Chronic Pain Scale evaluates pain-related disability and its dichotomous grading (high/low impact pain) can determine patient care pathways and in general high-impact pain patients have worse treatment outcomes. Individuals with low-impact TMD pain are thought to have better psychosocial functioning, more favorable disease course, and better ability to control pain, while individuals with high-impact pain can present with higher levels of physical and psychological symptoms. Thereby, there is reason to believe that individuals with low- and high-impact TMD pain could experience different pain trajectories over time. Our primary objective was to determine if short-term jaw pain fluctuations serve as a clinical marker for the impact status of TMD pain. To this end, we estimated the association between high/low impact pain status and jaw pain fluctuations over three visits (≤ 21-day-period) in 30 TMD cases. Secondarily, we measured the association between jaw pain intensity and pressure pain thresholds (PPT) over the face and hand, the latter measurements compared to matched pain-free controls (n = 17). Jaw pain fluctuations were more frequent among high-impact pain cases (n = 15) than low-impact pain cases (n = 15) (OR 5.5; 95% CI 1.2, 26.4; p value = 0.033). Jaw pain ratings were not associated with PPT ratings (p value > 0.220), suggesting different mechanisms for clinical versus experimental pain. Results from this proof-of-concept study suggest that targeted treatments to reduce short-term pain fluctuations in high-impact TMD pain is a potential strategy to achieve improved patient perception of clinical pain management outcomes.
- Published
- 2022
- Full Text
- View/download PDF
5. Multi-drug resistance and high mortality associated with community-acquired bloodstream infections in children in conflict-affected northwest Nigeria
- Author
-
Frederick Chukwumeze, Annick Lenglet, Ruth Olubiyo, Abdulhakeem Mohammed Lawal, Bukola Oluyide, Gbemisola Oloruntuyi, Cono Ariti, Diana Gomez, Harriet Roggeveen, Chijioke Nwankwo, Nwogu Ahamba Augustine, Abiodun Egwuenu, Guy Maloba, Mark Sherlock, Shoaib Muhammad, Heiman Wertheim, Joost Hopman, and Kate Clezy
- Subjects
Medicine ,Science - Abstract
Abstract Pediatric community-acquired bloodstream infections (CA-BSIs) in sub Saharan African humanitarian contexts are rarely documented. Effective treatment of these infections is additionally complicated by increasing rates of antimicrobial resistance. We describe the findings from epidemiological and microbiological surveillance implemented in pediatric patients with suspected CA-BSIs presenting for care at a secondary hospital in the conflict affected area of Zamfara state, Nigeria. Any child (> 2 months of age) presenting to Anka General Hospital from November 2018 to August 2020 with clinical severe sepsis at admission had clinical and epidemiological information and a blood culture collected at admission. Bacterial isolates were tested for antibiotic susceptibility. We calculated frequencies of epidemiological, microbiological and clinical parameters. We explored risk factors for death amongst severe sepsis cases using univariable and multivariable Poisson regression, adjusting for time between admission and hospital exit. We included 234 severe sepsis patients with 195 blood culture results. There were 39 positive blood cultures. Of the bacterial isolates, 14 were Gram positive and 18 were Gram negative; 5 were resistant to empiric antibiotics: methicillin-resistant Staphylococcus aureus (MRSA; n = 2) and Extended Spectrum Beta-Lactamase positive enterobacterales (n = 3). We identified no significant association between sex, age-group, ward, CA-BSI, appropriate intravenous antibiotic, malaria positivity at admission, suspected focus of sepsis, clinical severity and death in the multivariable regression. There is an urgent need for access to good clinical microbiological services, including point of care methods, and awareness and practice around rational antibiotic in healthcare staff in humanitarian settings to reduce morbidity and mortality from sepsis in children.
- Published
- 2021
- Full Text
- View/download PDF
6. Early warning for healthcare acquired infections in neonatal care units in a low-resource setting using routinely collected hospital data: The experience from Haiti, 2014-2018.
- Author
-
Annick Lenglet, Omar Contigiani, Cono Ariti, Estivern Evens, Kessianne Charles, Carl-Frédéric Casimir, Rodnie Senat Delva, Colette Badjo, Harriet Roggeveen, Barbara Pawulska, Kate Clezy, Melissa McRae, Heiman Wertheim, and Joost Hopman
- Subjects
Medicine ,Science - Abstract
In low-resource settings, detection of healthcare-acquired outbreaks in neonatal units relies on astute clinical staff to observe unusual morbidity or mortality from sepsis as microbiological diagnostics are often absent. We aimed to generate reliable (and automated) early warnings for potential clusters of neonatal late onset sepsis using retrospective data that could signal the start of an outbreak in an NCU in Port au Prince, Haiti, using routinely collected data on neonatal admissions. We constructed smoothed time series for late onset sepsis cases, late onset sepsis rates, neonatal care unit (NCU) mortality, maternal admissions, neonatal admissions and neonatal antibiotic consumption. An outbreak was defined as a statistical increase in any of these time series indicators. We created three outbreak alarm classes: 1) thresholds: weeks in which the late onset sepsis cases exceeded four, the late onset sepsis rates exceeded 10% of total NCU admissions and the NCU mortality exceeded 15%; 2) differential: late onset sepsis rates and NCU mortality were double the previous week; and 3) aberration: using the improved Farrington model for late onset sepsis rates and NCU mortality. We validated pairs of alarms by calculating the sensitivity and specificity of the weeks in which each alarm was launched and comparing each alarm to the weeks in which a single GNB positive blood culture was reported from a neonate. The threshold and aberration alarms were the strongest predictors for current and future NCU mortality and current LOS rates (p
- Published
- 2022
- Full Text
- View/download PDF
7. Altered brain responses to noxious dentoalveolar stimuli in high-impact temporomandibular disorder pain patients.
- Author
-
Connor M Peck, David A Bereiter, Lynn E Eberly, Christophe Lenglet, and Estephan J Moana-Filho
- Subjects
Medicine ,Science - Abstract
High-impact temporomandibular disorder (TMD) pain may involve brain mechanisms related to maladaptive central pain modulation. We investigated brain responses to stimulation of trigeminal sites not typically associated with TMD pain by applying noxious dentoalveolar pressure to high- and low-impact TMD pain cases and pain-free controls during functional magnetic resonance imaging (fMRI). Fifty female participants were recruited and assigned to one of three groups based on the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) and Graded Chronic Pain Scale: controls (n = 17), low-impact (n = 17) and high-impact TMD (n = 16). Multimodal whole-brain MRI was acquired following the Human Connectome Project Lifespan protocol, including stimulus-evoked fMRI scans during which painful dentoalveolar pressure was applied to the buccal gingiva of participants. Group analyses were performed using non-parametric permutation tests for parcellated cortical and subcortical neuroimaging data. There were no significant between-group differences for brain activations/deactivations evoked by the noxious dentoalveolar pressure. For individual group mean activations/deactivations, a gradient in the number of parcels surviving thresholding was found according to the TMD pain grade, with the highest number seen in the high-impact group. Among the brain regions activated in chronic TMD pain groups were those previously implicated in sensory-discriminative and motivational-affective pain processing. These results suggest that dentoalveolar pressure pain evokes abnormal brain responses to sensory processing of noxious stimuli in high-impact TMD pain participants, which supports the presence of maladaptive brain plasticity in chronic TMD pain.
- Published
- 2022
- Full Text
- View/download PDF
8. A natural history study to track brain and spinal cord changes in individuals with Friedreich’s ataxia: TRACK-FA study protocol
- Author
-
Nellie Georgiou-Karistianis, Louise A. Corben, Kathrin Reetz, Isaac M. Adanyeguh, Manuela Corti, Dinesh K. Deelchand, Martin B. Delatycki, Imis Dogan, Rebecca Evans, Jennifer Farmer, Marcondes C. França, William Gaetz, Ian H. Harding, Karen S. Harris, Steven Hersch, Richard Joules, James J. Joers, Michelle L. Krishnan, Michelle Lax, Eric F. Lock, David Lynch, Thomas Mareci, Sahan Muthuhetti Gamage, Massimo Pandolfo, Marina Papoutsi, Thiago J. R. Rezende, Timothy P. L. Roberts, Jens T. Rosenberg, Sandro Romanzetti, Jörg B. Schulz, Traci Schilling, Adam J. Schwarz, Sub Subramony, Bert Yao, Stephen Zicha, Christophe Lenglet, and Pierre-Gilles Henry
- Subjects
Medicine ,Science - Abstract
Introduction Drug development for neurodegenerative diseases such as Friedreich’s ataxia (FRDA) is limited by a lack of validated, sensitive biomarkers of pharmacodynamic response in affected tissue and disease progression. Studies employing neuroimaging measures to track FRDA have thus far been limited by their small sample sizes and limited follow up. TRACK-FA, a longitudinal, multi-site, and multi-modal neuroimaging natural history study, aims to address these shortcomings by enabling better understanding of underlying pathology and identifying sensitive, clinical trial ready, neuroimaging biomarkers for FRDA. Methods 200 individuals with FRDA and 104 control participants will be recruited across seven international study sites. Inclusion criteria for participants with genetically confirmed FRDA involves, age of disease onset ≤ 25 years, Friedreich’s Ataxia Rating Scale (FARS) functional staging score of ≤ 5, and a total modified FARS (mFARS) score of ≤ 65 upon enrolment. The control cohort is matched to the FRDA cohort for age, sex, handedness, and years of education. Participants will be evaluated at three study visits over two years. Each visit comprises of a harmonized multimodal Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) scan of the brain and spinal cord; clinical, cognitive, mood and speech assessments and collection of a blood sample. Primary outcome measures, informed by previous neuroimaging studies, include measures of: spinal cord and brain morphometry, spinal cord and brain microstructure (measured using diffusion MRI), brain iron accumulation (using Quantitative Susceptibility Mapping) and spinal cord biochemistry (using MRS). Secondary and exploratory outcome measures include clinical, cognitive assessments and blood biomarkers. Discussion Prioritising immediate areas of need, TRACK-FA aims to deliver a set of sensitive, clinical trial-ready neuroimaging biomarkers to accelerate drug discovery efforts and better understand disease trajectory. Once validated, these potential pharmacodynamic biomarkers can be used to measure the efficacy of new therapeutics in forestalling disease progression. Clinical trial registration ClinicalTrails.gov Identifier: NCT04349514.
- Published
- 2022
9. Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation
- Author
-
Sylvie Perreault, Robert Côté, Alice Dragomir, Brian White-Guay, Aurélie Lenglet, and Marc Dorais
- Subjects
Medicine ,Science - Abstract
Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical practice, but evidence of its effectiveness and safety compared with high-dose DOAC in patients with atrial fibrillation (AF) remains limited. We aimed to assess the effectiveness and safety of low-dose and high-dose DOACs in patients with AF with similar baseline characteristics. Methods We used a cohort of hospitalized patients with a primary or secondary diagnosis of AF after discharge to the community, whose data were stored in the Quebec administrative databases, from 2011 to 2017. Older adults with AF newly prescribed with rivaroxaban (15 or 20 mg) or apixaban (2.5 mg or 5 mg) were classified as under treatment (UT) and intent to treat (ITT). We used an inverse probability treatment weighting study of new users of rivaroxaban and apixaban to address confounding by indication. The primary effectiveness outcome was ischemic stroke/systemic embolism (SE), while the primary safety outcome was major bleeding (MB). We used Cox proportional models to estimate the marginal hazard ratios (HRs). Findings A total of 1,722 and 4,639 patients used low-dose and standard-dose rivaroxaban, respectively, while 3,833 and 6,773 patients used low-dose and standard-dose apixaban, respectively. No significant difference was observed in the incidence of comparative stroke/SE and MB between low-dose and standard-dose rivaroxaban, except for the risk of acute myocardial infarction (AMI), which was increased with the low dose in the UT analysis. For apixaban, no difference was found in the bleeding rates, but the risk of stroke/SE (HR: 1.95; 95% confidence interval (CI): 1.38–2.76) and death (HR: 1.99; 95% CI: 1.46–2.70) were greater in the low-dose group than in the standard-dose group in the UT analysis. Similar results were observed for the ITT analysis. Conclusion No significant differences were observed in the effectiveness or safety outcome between low-dose and standard-dose rivaroxaban, except for AMI. However, low-dose apixaban was associated with a greater risk of stroke/SE and death without a reduction in the bleeding rates.
- Published
- 2022
10. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.
- Author
-
Anita Mesic, Waliullah H Khan, Annick Lenglet, Lutgarde Lynen, Sadiqqulah Ishaq, Ei Hnin Hnin Phyu, Htay Thet Mar, Anthony Oraegbu, Mohammad Khaled Seddiq, Hashim Khan Amirzada, Jena Fernhout, Charity Kamau, Cono Ariti, Diana Gomez, and Tom Decroo
- Subjects
Medicine ,Science - Abstract
IntroductionAfghanistan is affected by one of the world's longest protracted armed conflicts, frequent natural disasters, disease outbreaks and large population movements and it suffers from a high burden of tuberculosis (TB), including rifampicin-resistant TB (RR-TB). The study shows Médecins Sans Frontières' experiences with care for patients with RR-TB in Kandahar Province. We describe the uptake of RR-TB treatment, how World Health Organisation criteria for the choice between the short and an individualized regimen were implemented, and treatment outcomes.MethodsThis is a retrospective cohort analysis of routinely collected data from RR-TB patients enrolled in care from 2016 until 2019. Descriptive analysis was performed to present characteristics of patients and treatment outcomes. Multivariable Cox analysis was performed to identify risk factors for having an unfavourable treatment outcome.ResultsOut of 146 enrolled RR-TB patients, 112 (76.7%) started treatment: 41 (36.6%) and 71 (63.4%) with the short and individualized treatment regimen, respectively. Of 82 with results for fluoroquinolone susceptibility, 39 (47.6%) had fluoroquinolone-resistant TB. Seven patients with initially fluoroquinolone-resistant TB and three pregnant women started the short regimen and 18 patients eligible for the short regimen started the injectable-free individualized regimen. Overall, six-month smear and culture conversion were 98.7% and 97.1%, respectively; treatment success was 70.1%. Known initial fluoroquinolone resistance (aHR 3.77, 95%CI:1.53-9.27) but not choice of regimen predicted having an unfavourable outcome.ConclusionEven though criteria for the choice of treatment regimen were not applied strictly, we have achieved acceptable outcomes in this cohort. To expand RR-TB care, treatment regimens should fit provision at primary health care level and take patient preferences into account.
- Published
- 2020
- Full Text
- View/download PDF
11. Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study
- Author
-
Rabab Debs, Jean-Yves Hogrel, Gaëlle Bruneteau, Nadine Le Forestier, Peter Bede, Pascal Laforêt, Sophie Blancho, Anthony Behin, Timothée Lenglet, Véronique Marchand-Pauvert, François Salachas, Giorgia Querin, Pierre-François Pradat, Tanya Stojkovic, Maria del Mar Amador, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Myologie, Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Association française contre les myopathies (AFM-Téléthon)-Sorbonne Université (SU), Etudes sur les sciences et les techniques (EST), Université Paris-Saclay, Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées (END-ICAP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré [AP-HP], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), H&R BLOCK, HRB: EIA-2017-019 Association Française contre les Myopathies, AFM Health Research Board, HRB Iris O'Brien Foundation Irish Institute of Clinical Neuroscience, IICN AFM-Téléthon: NCT0288587, This study was sponsored by the Association française contre les myopathies (AFM-Téléthon). Dr. Giorgia Querin, Dr. Timothée Lenglet, Dr. Rabab Debs, Dr. Tanya Stojkovic, Dr. Anthony Behin, Dr. François Salachas, Dr. Nadine Le Forestier, Dr. Maria del Mar Amador, Dr. Gaëlle Bruneteau, Dr. Sophie Blancho, Dr. Véronique Marchand-Pauvert: report no disclosures. Prof Pascal Laforêt receives funding for research and as an advisor or speaker from Sanofi Genzyme and Spark Therapeutics. Dr. Peter Bede is supported by the Health Research Board (HRB EIA-2017-019), the Andrew Lydon scholarship, the Irish Institute of Clinical Neuroscience (IICN), the Irish Motor Neuron Disease Association (IMNDA) and the Iris O'Brien Foundation. Dr. Jean-Yves Hogrel is co-inventor of the Myogrip and MyoPinch devices and did consultancy for Biogen and Sarepta. Dr Pierre- François Pradat receives funding as an advisor and speaker from Biogen., We are grateful for the generosity of all SMA patients who have kindly participated in this study. This study was supported by the Association Française contre les Myopathies (AFM-Téléthon). We also thank the Institut pour la Recherche sur la Moelle Épinière et l’Encephale (IRME) for their support of this the study. Peter Bede is supported by the Health Research Board (HRB EIA-2017-019), the Andrew Lydon scholarship, the Irish Institute of Clinical Neuroscience (IICN), the Irish Motor Neuron Disease Association (IMNDA) and the Iris O'Brien Foundation. The rest of the authors have no specific sponsors to declare., Supported by the Association Française contre les Myopathies (AFM-Téléthon, NCT0288587)., Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Myologie, Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Association française contre les myopathies (AFM-Téléthon). Dr. Giorgia Querin, Dr. Timothée Lenglet, Dr. Rabab Debs, Dr. Tanya Stojkovic, Dr. Anthony Behin, Dr. François Salachas, Dr. Nadine Le Forestier, Dr. Maria del Mar Amador, Dr. Gaëlle Bruneteau, Dr. Sophie Blancho, Dr. Véronique Marchand-Pauvert: report no disclosures. Prof Pascal Laforêt receives funding for research and as an advisor or speaker from Sanofi Genzyme and Spark Therapeutics. Dr. Peter Bede is supported by the Health Research Board (HRB EIA-2017-019), the Andrew Lydon scholarship, the Irish Institute of Clinical Neuroscience (IICN), the Irish Motor Neuron Disease Association (IMNDA) and the Iris O'Brien Foundation. Dr. Jean-Yves Hogrel is co-inventor of the Myogrip and MyoPinch devices and did consultancy for Biogen and Sarepta. Dr Pierre- François Pradat receives funding as an advisor and speaker from Biogen.
- Subjects
Adult ,medicine.medical_specialty ,Longitudinal study ,Neurology ,[SDV]Life Sciences [q-bio] ,Deltoid curve ,Spinal Muscular Atrophies of Childhood ,Outcome measures ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Outcome Assessment, Health Care ,Humans ,Medicine ,Longitudinal Studies ,Muscle Strength ,030212 general & internal medicine ,Muscle, Skeletal ,Neuroradiology ,Longitudinal progression ,business.industry ,SMA ,Spinal cord ,3. Good health ,Clinical trial ,medicine.anatomical_structure ,Sample size determination ,Adult SMA ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,MUNIX - Abstract
International audience; Objective: The aim of this study was the comprehensive characterisation of longitudinal clinical, electrophysiological and neuroimaging measures in type III and IV adult spinal muscular atrophy (SMA) with a view to propose objective monitoring markers for future clinical trials. Methods: Fourteen type III or IV SMA patients underwent standardised assessments including muscle strength testing, functional evaluation (SMAFRS and MFM), MUNIX (abductor pollicis brevis, APB; abductor digiti minimi, ADM; deltoid; tibialis anterior, TA; trapezius) and quantitative cervical spinal cord MRI to appraise segmental grey and white matter atrophy. Patients underwent a follow-up assessment with the same protocol 24 months later. Longitudinal comparisons were conducted using the Wilcoxon-test for matched data. Responsiveness was estimated using standardized response means (SRM) and a composite score was generated based on the three most significant variables. Results: Significant functional decline was observed based on SMAFRS (p = 0.019), pinch and knee flexion strength (p = 0.030 and 0.027), MUNIX and MUSIX value in the ADM (p = 0.0006 and 0.043) and in TA muscle (p = 0.025). No significant differences were observed based on cervical MRI measures. A significant reduction was detected in the composite score (p = 0.0005, SRM = −1.52), which was the most responsive variable and required a smaller number of patients than single variables in the estimation of sample size for clinical trials. Conclusions: Quantitative strength testing, SMAFRS and MUNIX readily capture disease progression in adult SMA patients. Composite multimodal scores increase predictive value and may reduce sample size requirements in clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
12. Uremic Toxins and Vascular Dysfunction
- Author
-
Isabelle Six, Nadia Flissi, Gaëlle Lenglet, Loïc Louvet, Said Kamel, Marlène Gallet, Ziad A. Massy, and Sophie Liabeuf
- Subjects
chronic kidney disease ,uremic toxins ,vascular dysfunction ,Medicine - Abstract
Vascular dysfunction is an essential element found in many cardiovascular pathologies and in pathologies that have a cardiovascular impact such as chronic kidney disease (CKD). Alteration of vasomotricity is due to an imbalance between the production of relaxing and contracting factors. In addition to becoming a determining factor in pathophysiological alterations, vascular dysfunction constitutes the first step in the development of atherosclerosis plaques or vascular calcifications. In patients with CKD, alteration of vasomotricity tends to emerge as being a new, less conventional, risk factor. CKD is characterized by the accumulation of uremic toxins (UTs) such as phosphate, para-cresyl sulfate, indoxyl sulfate, and FGF23 and, consequently, the deleterious role of UTs on vascular dysfunction has been explored. This accumulation of UTs is associated with systemic alterations including inflammation, oxidative stress, and the decrease of nitric oxide production. The present review proposes to summarize our current knowledge of the mechanisms by which UTs induce vascular dysfunction.
- Published
- 2020
- Full Text
- View/download PDF
13. Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: A multicenter prospective study
- Author
-
Aude-Marie Grapperon, Annie Verschueren, Elisabeth Jouve, Régine Morizot-Koutlidis, Timothée Lenglet, Pierre-François Pradat, François Salachas, Emilien Bernard, Stéphanie Delstanche, Alain Maertens de Noordhout, Nathalie Guy, Véronique Danel, Arnaud Delval, Emilien Delmont, Anne-Sophie Rolland, null PULSE Study Group, Laurent Jomir, David Devos, François Wang, and Shahram Attarian
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Physical medicine and rehabilitation ,Physiology (medical) ,Humans ,Medicine ,Prospective Studies ,Motor Neuron Disease ,Amyotrophic lateral sclerosis ,Prospective cohort study ,Ulnar Nerve ,Aged ,Motor Neurons ,business.industry ,Upper motor neuron ,Stimulation technique ,Amyotrophic Lateral Sclerosis ,Middle Aged ,Evoked Potentials, Motor ,bacterial infections and mycoses ,medicine.disease ,Transcranial Magnetic Stimulation ,Electric Stimulation ,Sensory Systems ,Transcranial magnetic stimulation ,medicine.anatomical_structure ,Neurology ,Multicenter study ,Diagnostic assessment ,Female ,Neurology (clinical) ,business ,Conduction time - Abstract
Objective To evaluate the relevance of transcranial magnetic stimulation (TMS) using triple stimulation technique (TST) to assess corticospinal function in amyotrophic lateral sclerosis (ALS) in a large-scale multicenter study. Methods Six ALS centers performed TST and conventional TMS in upper limbs in 98 ALS patients during their first visit to the center. Clinical evaluation of patients included the revised ALS Functional Rating Scale (ALSFRS-R) and upper motor neuron (UMN) score. Results TST amplitude ratio was decreased in 62% of patients whereas conventional TMS amplitude ratio was decreased in 25% of patients and central motor conduction time was increased in 16% of patients. TST amplitude ratio was correlated with ALSFRS-R and UMN score. TST amplitude ratio results were not different between the centers. Conclusions TST is a TMS technique applicable in daily clinical practice in ALS centers for the detection of UMN dysfunction, more sensitive than conventional TMS and related to the clinical condition of the patients. Significance This multicenter study shows that TST can be a routine clinical tool to evaluate UMN dysfunction at the diagnostic assessment of ALS patients.
- Published
- 2021
- Full Text
- View/download PDF
14. Model of care, Noma Children’s Hospital, northwest Nigeria
- Author
-
Joseph Samuel, Annick Lenglet, Adeniyi Semiyu Adetunji, Annette de Jong, Elise Farley, Mark Sherlock, Nura Abubakar, Mohana Amirtharajah, Monique Pereboom, Muhammad Shoaib, Shafi'u Isah, Bukola Oluyide, and Karla Bil
- Subjects
Male ,medicine.medical_specialty ,Best practice ,Nigeria ,Noma ,Acute care ,cancrum oris ,Humans ,Medicine ,Limited evidence ,noma ,Child ,Surgical treatment ,business.industry ,Public Health, Environmental and Occupational Health ,Tropical disease ,Hospitals, Pediatric ,model of care ,medicine.disease ,Infectious Diseases ,Child, Preschool ,Family medicine ,Female ,Parasitology ,Christian ministry ,Comprehensive Health Care ,business - Abstract
The Nigerian Ministry of Health has been offering care for noma patients for many years at the Noma Children's Hospital (NCH) in Sokoto, northwest Nigeria, and Medecins Sans Frontieres has supported these initiatives since 2014. The comprehensive model of care consists of four main components: acute care, care for noma sequelae, integrated hospital-based services and community-based services. The model of care is based on the limited evidence available for prevention and treatment of noma and follows WHO's protocols for acute patients as well as best practice guidelines for the surgical treatment of noma survivors. The model is updated continually as new evidence becomes available, including evidence generated through the operational research studies performed at NCH. By describing the model of care, we wish to share the lessons learned with other actors working in the noma and neglected tropical disease sphere in the hope of guiding programme development.
- Published
- 2021
- Full Text
- View/download PDF
15. Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
- Author
-
Ziad A. Massy, François-Ludovic Sauvage, Gabriel Choukroun, Marie Essig, Souleiman El Balkhi, Aurélie Lenglet, Mohamad Ali Rahali, Sophie Liabeuf, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], CHU Limoges, Amgen Eli Lilly and Company GlaxoSmithKline, GSK Baxter International FMC Corporation, FMC Meso Scale Diagnostics, MSD, We thank Prof. Albert Fournier, who initiated this clinical study. We also thank Amiens University Hospital, and especially the Clinical Research and Innovation Directorate (for logistical support), the Clinical Research Center (for study management), and the Department of Nephrology Internal Medicine, Dialysis, Transplantation and Intensive Care. Last, we thank the patients and physicians at the 18 dialysis centers for their participation in the NICOREN trial., Ziad A. Massy reports grants and Congress Travel support from Amgen, Baxter, Otsuka, and Sanofi-Genzyme, grants from the French Government, MSD, GSK, Lilly, and FMC, and Receipt of honoraria or consultation fees for the Charities from Daichi and Astellas, outside the submitted work., and HAL UVSQ, Équipe
- Subjects
Niacinamide ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Population ,Serum albumin ,Sevelamer ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Original Research Article ,Risk factor ,education ,Serum Albumin ,030203 arthritis & rheumatology ,Pharmacology ,education.field_of_study ,Protein Carbamylation ,biology ,Nicotinamide ,business.industry ,Albumin ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Endocrinology ,chemistry ,biology.protein ,Urea ,Kidney Failure, Chronic ,business ,medicine.drug ,Kidney disease - Abstract
Background and Objective In end-stage kidney disease, high urea levels promote the carbamylation of lysine side chains on a variety of proteins, including albumin. Albumin carbamylation has been identified as a risk factor for mortality and sevelamer led to a decrease in urea levels in dialysis patients. In the present secondary analysis of the NICOREN trial, we investigated the putative impacts of sevelamer and nicotinamide on albumin carbamylation, and the potential correlation between carbamylation and vascular calcifications. Methods All possible carbamylation of circulating albumin were screened for with high-resolution liquid chromatography-tandem mass spectrometry. Levels of three carbamylated peptides were then measured as a guide to the extent of albumin carbamylation. Carbamylation was measured at baseline in 55 patients included in the NICOREN trial and 29 patients at 24 weeks of treatment. Calcifications on plain radiographs were quantified as the Kauppila score and the Adragao score. Results Baseline albumin carbamylation was present at three different sites in subjects with end-stage kidney disease. At baseline, we observed only a correlation between urea and the KQTA carbamylation site in these patients. Albumin carbamylation levels did not decrease after 24 weeks of treatment with either sevelamer or nicotinamide. Furthermore, the proportion of carbamylated serum albumin was not correlated with vascular calcification scores in this population. Conclusions Our results confirmed the presence of carbamylated albumin in patients with end-stage kidney disease and demonstrated the presence of carbamylation beyond the LRVP residues. The results also demonstrated the lack of impact of sevelamer or nicotinamide on albumin carbamylation levels. Therapeutic strategies to lower carbamylation load should probably be focused on direct anti-carbamylation processes and/or potentially anti-inflammatory therapies. Supplementary Information The online version contains supplementary material available at 10.1007/s40268-021-00350-7.
- Published
- 2021
- Full Text
- View/download PDF
16. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies
- Author
-
Giulia Berzero, Nathalie Gaspar, Thierry Maisonobe, Capucine Mouthon-Reignier, Julien Lazarovici, Timothée Lenglet, A. K. Wang, Corinne Dupel-Pottier, Weiss Nicolas, Karine Viala, Patrice Carde, David H. Adams, Kevin Bihan, Cécile Cauquil, Guillaume Fargeot, Benramdane Riad, Andoni Echaniz-Laguna, Dimitri Psimaras, Camille Tafani, Laurent Magy, Laure Thomas, Maeva Stephant, Fargeot, G., Dupel-Pottier, C., Stephant, M., Lazarovici, J., Thomas, L., Mouthon-Reignier, C., Riad, B., Carde, P., Berzero, G., Tafani, C., Nicolas, W., Viala, K., Maisonobe, T., Lenglet, T., Wang, A., Magy, L., Bihan, K., Gaspar, N., Adams, D., Echaniz-Laguna, A., Cauquil, C., and Psimaras, D.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neurology ,Antineoplastic Agents ,Guillain-Barre Syndrome ,Gastroenterology ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Brentuximab vedotin ,Adverse effect ,Aged ,Brentuximab Vedotin ,Hematology ,business.industry ,Lymphoma, Non-Hodgkin ,Polyradiculoneuropathy ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Lymphoma ,Psychiatry and Mental health ,Peripheral neuropathy ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Monomethyl auristatin E ,chemistry ,oncology ,haematology ,neuropathy ,Female ,Surgery ,neuromuscular ,Neurology (clinical) ,neurophysiology ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Brentuximab vedotin (BV) is an antibody-drug conjugate composed by an anti-CD30 monoclonal antibody and the anti-microtubule agent monomethyl auristatin E, used for the treatment of relapsed/refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma. Peripheral neuropathy is a frequent adverse event of BV treatment, affecting up to 60% to 70% of patients.1 It usually consists of a mild axonal, length-dependent, sensory neuropathy, characterised by numbness and tingling of fingers and toes,1 2 related to the toxic effect of monomethyl auristatin E on axonal microtubules.3 Nonetheless, immune-mediated peripheral neuropathies characterised by prominent motor impairment have also been described,4 suggesting that, similarly to other antineoplastic agents, BV might have the potential to induce or exacerbate inflammatory polyradiculoneuropathies. The aim of this study was to assess the characteristics of inflammatory demyelinating polyradiculoneuropathy associated with BV treatment. ### Patients and methods We performed a retrospective research in seven French neurology departments, for all patients who were admitted between January 2013 and December 2019 to investigate a peripheral neuropathy appeared during BV treatment. We selected patients meeting Sjevar et al criteria for the diagnosis of Guillain-Barre syndrome (GBS) (level 1 of diagnostic certainty) or meeting ‘definite’ criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to 2010 European Federation of Neurological Societies/Peripheral Nerve Society guideline. We considered the onset as acute, subacute or chronic if the disease nadir was reached within 4 weeks, between 4 to 8 …
- Published
- 2020
- Full Text
- View/download PDF
17. Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease
- Author
-
European Uremic Toxin (EUTox) Work Group, Ziad A. Massy, Horst-Dieter Lemke, Raymond Vanholder, Gabriel Choukroun, Aurélie Lenglet, Lucie Desjardins, and Sophie Liabeuf
- Subjects
uremic toxins ,free light chain ,chronic kidney disease ,Medicine - Abstract
Immunoglobulin free light chains (FLCs) form part of the middle molecule group of uremic toxins. Accumulation of FLCs has been observed in patients with chronic kidney disease (CKD). The aim of the present study was to measure FLC levels in patients at different CKD stages and to assess putative associations between FLC levels on one hand and biochemical/clinical parameters and mortality on the other. One hundred and forty patients at CKD stages 2-5D were included in the present study. Routine clinical biochemistry assays and assays for FLC kappa (κ) and lambda (λ) and other uremic toxins were performed. Vascular calcification was evaluated using radiological techniques. The enrolled patients were prospectively monitored for mortality. Free light chain κ and λ levels were found to be elevated in CKD patients (especially in those on hemodialysis). Furthermore, FLC κ and λ levels were positively correlated with inflammation, aortic calcification and the levels of various uremic toxins levels. A multivariate linear regression analysis indicated that FLC κ and λ levels were independently associated with CKD stages and β2 microglobulin levels. Elevated FLC κ and λ levels appeared to be associated with mortality. However, this association disappeared after adjustment for a propensity score including age, CKD stage and aortic calcification. In conclusion, our results indicate that FLC κ and λ levels are elevated in CKD patients and are associated with inflammation, vascular calcification and levels of other uremic toxins. The observed link between elevated FLC levels and mortality appears to depend on other well-known factors.
- Published
- 2013
- Full Text
- View/download PDF
18. Guillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature
- Author
-
Perrine Devic, Alaina Borden, Karine Viala, Bastien Herlin, Nicolas Weiss, Evangelia Pappa, Giulia Berzero, Dimitri Psimaras, Thierry Maisonobe, Timothée Lenglet, Damien Ricard, Denis Maillet, Camille Tafani, Pappa, E., Berzero, G., Herlin, B., Ricard, D., Tafani, C., Devic, P., Maillet, D., Borden, A., Viala, K., Maisonobe, T., Lenglet, T., Weiss, N., and Psimaras, D.
- Subjects
Cancer Research ,Pediatrics ,medicine.medical_specialty ,endocrine system diseases ,Side effect ,medicine.medical_treatment ,chemistry.chemical_element ,Disease ,Guillain-Barre Syndrome ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,Aged ,Platinum ,Retrospective Studies ,Chemotherapy ,Guillain-Barre syndrome ,business.industry ,Electromyoneurography ,Middle Aged ,medicine.disease ,Discontinuation ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Female ,Brief Communications ,Complication ,business ,030217 neurology & neurosurgery - Abstract
Platinum-based chemotherapy is commonly associated with toxic sensory neuropathies, but also, although rarely, with Guillain-Barré syndrome (GBS). We describe five patients who developed GBS while receiving platinum-based chemotherapy for a solid tumor and report the five cases published so far. Most patients had received cumulative platinum doses below known neurotoxic levels, and all of them had an optimal outcome after platinum discontinuation, associated in most cases with administration of intravenous immunoglobulin. Clinical presentation, electroneuromyography, and cerebrospinal fluid analysis help clinicians to differentiate GBS from toxic neuropathy. Platinum compounds are the only chemotherapeutic agents used for solid tumors that have been associated to GBS. Thus, we propose that GBS may constitute a non–dose-dependent side effect of platinum drugs and that awareness needs to be raised among oncologists on this rare but potentially life-threatening complication of platinum chemotherapy. Implications for Practice: Many patients on platinum-based chemotherapy for solid tumors develop sensory neuropathy, a common dose-dependent side effect. The authors propose that Guillain-Barré syndrome may constitute an immune-mediated, non-dose-related side effect of platinum-based chemotherapy. Prompt diagnosis of Guillain-Barré syndrome and distinction from classical toxic neuropathy are crucial for optimal treatment. Platinum discontinuation, associated if needed to intravenous immunoglobulin administration, radically changes the course of the disease and minimizes neurological sequelae.
- Published
- 2019
- Full Text
- View/download PDF
19. Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features
- Author
-
Christophe Vandendries, Julie Zyss, T. Lenglet, Karine Viala, Charline Benoit, Thierry Maisonobe, Juliette Svahn, and Rabab Debs
- Subjects
Pathology ,medicine.medical_specialty ,Neural Conduction ,Mismatch negativity ,Motor nerve ,Polyneuropathies ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Peripheral Nerves ,Retrospective Studies ,Plexus ,business.industry ,General Neuroscience ,Polyradiculoneuropathy ,medicine.disease ,Plexopathy ,Lumbosacral plexus ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Somatosensory evoked potential ,030220 oncology & carcinogenesis ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Multifocal motor neuropathy - Abstract
Focal chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is defined as involving the brachial or lumbosacral plexus, or one or more peripheral nerves in one upper or one lower limb (monomelic distribution). However, other auto-immune neuropathies such as Lewis-Sumner syndrome (LSS) and multifocal motor neuropathy (MMN) can also have a focal onset. From a retrospective cohort of 30 focal CIDP patients with a monomelic onset dating back at least 2 years, we distinguished patients with plexus involvement (focal demyelinating plexus neuropathy [F-PN], n = 18) from those with sensory or sensorimotor (F-SMN, n = 7), or purely motor (F-MN, n = 5) impairment located in one or several peripheral nerves. Few (39%) F-PN patients had motor nerve conduction abnormalities, but the majority showed proximal conduction abnormalities in somatosensory evoked potentials (80%), and all had focal hypertrophy and/or increased short tau inversion recovery image signal intensity on plexus MRI. Impairment remained monomelic in most (94%) F-PN patients, whereas abnormalities developed in other limbs in 57% of F-SMN, and 40% of F-MN patients (P = .015). The prognosis of F-PN patients was significantly better: none had an ONLS score > 2 at the final follow-up visit, vs 43% of F-SMN patients and 40% of F-MN patients (P = .026). Our findings from a large cohort of focal CIDP patients confirm the existence of different entities that are typically categorized under this one term: on the one hand, patients with a focal plexus neuropathy and on the other, patients with monomelic sensori-motor or motor involvement of peripheral nerves. These two last subgroups appeared to be more likely to evolve to LSS or MMN phenotype, when F-PN patients have a more distinctive long-term, focal, benign course.
- Published
- 2021
- Full Text
- View/download PDF
20. Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
- Author
-
Alice Dragomir, Marie-Pierre Dubé, Aurélie Lenglet, Sylvie Perreault, B. White-Guay, James M. Brophy, Robert Côté, Marc Dorais, Simon de Denus, Jean-Claude Tardif, and Mireille E. Schnitzer
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Pyridones ,medicine.drug_class ,030106 microbiology ,Population ,030204 cardiovascular system & hematology ,law.invention ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Rivaroxaban ,Randomized controlled trial ,law ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Pharmacology (medical) ,Propensity Score ,education ,Aged ,education.field_of_study ,Dose-Response Relationship, Drug ,business.industry ,Hazard ratio ,Anticoagulant ,Treatment Outcome ,Cohort ,Pyrazoles ,Apixaban ,business ,medicine.drug ,Cohort study - Abstract
Study objective Observational studies assessing direct oral anticoagulant (DOACs) dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high-dose DOACs compared to those in randomized controlled trials (RCTs). Effectiveness and safety of high-dose DOACs relative to apixaban in a real-world AF population need to be addressed. The aim is to assess comparative effectiveness and safety of high-dose rivaroxaban relative to apixaban. Design We conducted a cohort study. Setting We built a cohort of patients hospitalized and discharged in community with a primary or secondary AF diagnosis from 2011-2017 using Quebec administrative databases (Med-Echo and RAMQ). Patients Cohort entry was defined as the first OAC claim in new users of high-dose rivaroxaban and apixaban, with no OAC claims in the prior year. Intervention To compare effectiveness and safety of high-dose rivaroxaban to apixaban. Measurement We ascertained patient demographics, comorbidities, CHA2DS2-VASc and HASBLED scores and Charlson score within 3 years prior to cohort entry. Primary effectiveness and safety were a composite of ischemic stroke/systemic thrombosis, death, myocardial infarction, and of intracranial bleeding (ICH), extracranial major bleeding, in the first year following drug initiation. We conducted propensity score matching and estimated hazard ratios (HRs) for outcomes using Cox proportional hazard models. All the analyses were conducted to account for competing risks. Main results The cohort consisted of 4,632 and 6,771 patients received high-dose rivaroxaban and apixaban, respectively. High-dose rivaroxaban users were younger with a mean age of 73.2 years, presented less associated comorbidities and had lower CHA2DS2-VASc scores compared to apixaban. High-dose rivaroxaban at the intention to treat was associated with a higher risk of stroke/SE/death (HR 1.21, 95% CI 1.04-1.40) and worse composite effectiveness (HR 1.21: 1.05-1.40); under treatment exposure, those values were at HR (1.66: 1.21-2.29) and HR (1.58:1.19-2.10), respectively. And, rivaroxaban presented a less favorable safety profile relative to apixaban. Conclusion In this study, composite effectiveness and safety varied between rivaroxaban and apixaban. High-dose apixaban was observed to have a better effectiveness and safety.
- Published
- 2021
- Full Text
- View/download PDF
21. Usefulness of a Visual Analog Scale for Measuring Anxiety in Hospitalized Patients Experiencing Pain: A Multicenter Cross-Sectional Study
- Author
-
Quentin Lenglet, Karine Lacroix, Tristan Pascart, Sahara Graf, Adeline Versavel, Roman Chiquet, Marie Moukagni, Guillaume Bouquet, Vincent Ducoulombier, Amelie Devaux, Alexandre Kone, Bernard Leroy, Eric Houvenagel, Stéphane Verdun, Gauthier Calais, Robert Jeanson, Antoine Lefebvre, Marie Ledein, Adeline Grimbert, Benoit Coviaux, Fabienne Martellier, and Didier Duthoit
- Subjects
Adult ,Male ,medicine.medical_specialty ,Psychometrics ,Hospitalized patients ,Cross-sectional study ,Visual analogue scale ,Population ,Psychological intervention ,Anxiety ,Hospital Anxiety and Depression Scale ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,030212 general & internal medicine ,education ,Aged ,Pain Measurement ,Advanced and Specialized Nursing ,education.field_of_study ,030504 nursing ,business.industry ,Middle Aged ,Confidence interval ,Hospitalization ,Cross-Sectional Studies ,Physical therapy ,Female ,medicine.symptom ,0305 other medical science ,business - Abstract
Background Anxiety is common in hospitalized patients and can worsen pain or lead to unsuccessful pain relief. Aims The purpose of this study was to evaluate the usefulness of measuring anxiety with a visual analog scale (VAS) in the hospitalized patient experiencing pain. Design We conducted a multiple-center cross-sectional study. Participants/Subjects Adult inpatients experiencing moderate to severe pain defined by a pain VAS score ≥40 of 100 were included. Methods Pain and anxiety data were collected using the following instruments: pain VAS, anxiety VAS, State Anxiety Scale of the Spielberger State-Trait Anxiety Inventory (STAI-YA) and Anxiety Subscale of the Hospital Anxiety and Depression Scale (HAD-A). Results Data were collected from 394 patients. Of those patients, 43.6% (171 of 392) and 36.6% (143 of 391) had significant anxiety according to STAI-Ya and HAD-A, respectively. Correlation was good between anxiety-VAS and STAI-YA (ρ = 0.67 [95% confidence interval 0.61-0.72]) and moderate between anxiety VAS and HAD-D (ρ = 0.48 [0.39-0.56]). The main factor predictive of situational anxiety was history of anxiety-depression symptoms (odds ratio = 2.95 [1.93-4.56]). For anxiety VAS score ≥ 40 of 100, the sensitivity for detecting anxiety was 81% with 70% specificity. Conclusion This study confirmed the high prevalence of anxiety among inpatients experiencing pain, demonstrated the capacity of a VAS to assess this anxiety, determined an anxiety VAS cutoff level to screen for significant anxiety, and identified risk factors of anxiety in this population. Anxiety VAS has been found to be an easy-to-use method familiar to caregivers, with all the advantages needed for an effective screening instrument. An anxiety VAS score ≥40 of 100 would thus warrant particular attention to adapt care to the patient's anxiety-related pain and initiate specific therapeutic interventions.
- Published
- 2020
- Full Text
- View/download PDF
22. Cervical Spinal Cord Atrophy Profile in Adult SMN1-Linked SMA.
- Author
-
Mohamed-Mounir El Mendili, Timothée Lenglet, Tanya Stojkovic, Anthony Behin, Raquel Guimarães-Costa, François Salachas, Vincent Meininger, Gaelle Bruneteau, Nadine Le Forestier, Pascal Laforêt, Stéphane Lehéricy, Habib Benali, and Pierre-François Pradat
- Subjects
Medicine ,Science - Abstract
PURPOSE:The mechanisms underlying the topography of motor deficits in spinal muscular atrophy (SMA) remain unknown. We investigated the profile of spinal cord atrophy (SCA) in SMN1-linked SMA, and its correlation with the topography of muscle weakness. MATERIALS AND METHODS:Eighteen SMN1-linked SMA patients type III/V and 18 age/gender-matched healthy volunteers were included. Patients were scored on manual muscle testing and functional scales. Spinal cord was imaged using 3T MRI system. Radial distance (RD) and cord cross-sectional area (CSA) measurements in SMA patients were compared to those in controls and correlated with strength and disability scores. RESULTS:CSA measurements revealed a significant cord atrophy gradient mainly located between C3 and C6 vertebral levels with a SCA rate ranging from 5.4% to 23% in SMA patients compared to controls. RD was significantly lower in SMA patients compared to controls in the anterior-posterior direction with a maximum along C4 and C5 vertebral levels (p-values < 10-5). There were no correlations between atrophy measurements, strength and disability scores. CONCLUSIONS:Spinal cord atrophy in adult SMN1-linked SMA predominates in the segments innervating the proximal muscles. Additional factors such as neuromuscular junction or intrinsic skeletal muscle defects may play a role in more complex mechanisms underlying weakness in these patients.
- Published
- 2016
- Full Text
- View/download PDF
23. Brain Structure and Degeneration Staging in Friedreich Ataxia: Magnetic Resonance Imaging Volumetrics from the ENIGMA‐Ataxia Working Group
- Author
-
Caterina Tonon, Thiago Junqueira Ribeiro de Rezende, Christophe Lenglet, Wolfgang Nachbauer, Jörg B. Schulz, Kathrin Reetz, Christoph Scherfler, James M. Joers, Francesco Saccà, Gary F. Egan, Carlos R. Hernandez-Castillo, Marinela Vavla, Dagmar Timmann, Mario Mascalchi, Alberto R. M. Martinez, Sophia Göricke, Chiara Marzi, Paul M. Thompson, Imis Dogan, Sirio Cocozza, Giuseppe Pontillo, Stefania Evangelisti, David Neil Manners, Louise A. Corben, Pierre-Gilles Henry, Laura Ludovica Gramegna, Diane Hutter, Filippo Arrigoni, Ian H. Harding, Raffaele Lodi, Stefano Diciotti, Chiara Pane, Sophia I. Thomopoulos, Marcondes C. França, Andreas Deistung, Neda Jahanshad, Sandro Romanzetti, Pramod Kumar Pisharady, Andrea Martinuzzi, Ambra Stefani, Stefania Tirelli, Sylvia Boesch, Martin B. Delatycki, Sidhant Chopra, Denis Peruzzo, Arturo Brunetti, Nellie Georgiou-Karistianis, Claudia Testa, Harding I.H., Chopra S., Arrigoni F., Boesch S., Brunetti A., Cocozza S., Corben L.A., Deistung A., Delatycki M., Diciotti S., Dogan I., Evangelisti S., Franca M.C., Goricke S.L., Georgiou-Karistianis N., Gramegna L.L., Henry P.-G., Hernandez-Castillo C.R., Hutter D., Jahanshad N., Joers J.M., Lenglet C., Lodi R., Manners D.N., Martinez A.R.M., Martinuzzi A., Marzi C., Mascalchi M., Nachbauer W., Pane C., Peruzzo D., Pisharady P.K., Pontillo G., Reetz K., Rezende T.J.R., Romanzetti S., Sacca F., Scherfler C., Schulz J.B., Stefani A., Testa C., Thomopoulos S.I., Timmann D., Tirelli S., Tonon C., Vavla M., Egan G.F., and Thompson P.M.
- Subjects
Adult ,Male ,Cerebellum ,Ataxia ,Medizin ,Pyramidal Tracts ,Grey matter ,Young Adult ,Image Processing, Computer-Assisted ,Humans ,Medicine ,Pyramidal Tract ,ddc:610 ,Age of Onset ,business.industry ,Brain ,Voxel-based morphometry ,Middle Aged ,Spinal cord ,Magnetic Resonance Imaging ,Dentate nucleus ,medicine.anatomical_structure ,Neurology ,Friedreich Ataxia ,Brain size ,Disease Progression ,Female ,Neurology (clinical) ,Brainstem ,medicine.symptom ,business ,Neuroscience ,Human - Abstract
Objective: Friedreich ataxia (FRDA) is an inherited neurological disease defined by progressive movement incoordination. We undertook a comprehensive characterization of the spatial profile and progressive evolution of structural brain abnormalities in people with FRDA. Methods: A coordinated international analysis of regional brain volume using magnetic resonance imaging data charted the whole-brain profile, interindividual variability, and temporal staging of structural brain differences in 248 individuals with FRDA and 262 healthy controls. Results: The brainstem, dentate nucleus region, and superior and inferior cerebellar peduncles showed the greatest reductions in volume relative to controls (Cohen d= 1.5–2.6). Cerebellar gray matter alterations were most pronounced in lobules I–VI (d= 0.8), whereas cerebral differences occurred most prominently in precentral gyri (d= 0.6) and corticospinal tracts (d= 1.4). Earlier onset age predicted less volume in the motor cerebellum (rmax= 0.35) and peduncles (rmax= 0.36). Disease duration and severity correlated with volume deficits in the dentate nucleus region, brainstem, and superior/inferior cerebellar peduncles (rmax= −0.49); subgrouping showed these to be robust and early features of FRDA, and strong candidates for further biomarker validation. Cerebral white matter abnormalities, particularly in corticospinal pathways, emerge as intermediate disease features. Cerebellar and cerebral gray matter loss, principally targeting motor and sensory systems, preferentially manifests later in the disease course. Interpretation: FRDA is defined by an evolving spatial profile of neuroanatomical changes beyond primary pathology in the cerebellum and spinal cord, in line with its progressive clinical course. The design, interpretation, and generalization of research studies and clinical trials must consider neuroanatomical staging and associated interindividual variability in brain measures. ANN NEUROL 2021;90:570–583.
- Published
- 2021
- Full Text
- View/download PDF
24. Exploring factors influencing patient mortality and loss to follow-up in two paediatric hospital wards in Zamfara, North-West Nigeria, 2016-2018
- Author
-
Augusto, Orvalho, Maisa, Anna, Lawal, Abdulhakeem Mohammed, Islam, Tarikul, Nwankwo, Chijioke, Oluyide, Bukola, Fotso, Adolphe, Roggeveen, Harriet, van der Kam, Saskia, Ariti, Cono, Bil, Karla, and Lenglet, Annick
- Subjects
Male ,Viral Diseases ,Pediatrics ,Health Services Accessibility ,Geographical Locations ,Patient Admission ,Medical Conditions ,Medicine and Health Sciences ,Poisson Distribution ,Child ,Multidisciplinary ,Geography ,Hospitals, Pediatric ,Hospitals ,Infectious Diseases ,Child, Preschool ,Child Mortality ,Regression Analysis ,Medicine ,Female ,Research Article ,Death Rates ,Science ,Nigeria ,All institutes and research themes of the Radboud University Medical Center ,Population Metrics ,Sepsis ,Parasitic Diseases ,Humans ,Retrospective Studies ,Nutrition ,Population Biology ,Malnutrition ,Infant, Newborn ,Infant ,Biology and Life Sciences ,Tropical Diseases ,Malaria ,Health Care ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Health Care Facilities ,Age Groups ,Multivariate Analysis ,People and Places ,Africa ,Population Groupings ,Follow-Up Studies ,Measles - Abstract
Introduction Child mortality has been linked to infectious diseases, malnutrition and lack of access to essential health services. We investigated possible predictors for death and patients lost to follow up (LTFU) for paediatric patients at the inpatient department (IPD) and inpatient therapeutic feeding centre (ITFC) of the Anka General Hospital (AGH), Zamfara State, Nigeria, to inform best practices at the hospital. Methods We conducted a retrospective cohort review study using routinely collected data of all patient admissions to the IPD and ITFC with known hospital exit status between 2016 and 2018. Unadjusted and adjusted rate ratios (aRR) and respective 95% confidence intervals (95% CI) were calculated using Poisson regression to estimate the association between the exposure variables and mortality as well as LTFU. Results The mortality rate in IPD was 22% lower in 2018 compared to 2016 (aRR 0.78; 95% CI 0.66–0.93) and 70% lower for patients coming from lead-affected villages compared to patients from other villages (aRR 0.30; 95% CI 0.19–0.48). The mortality rate for ITFC patients was 41% higher during rainy season (aRR 1.41; 95% CI 1.2–1.6). LTFU rates in ITFC increased in 2017 and 2018 when compared to 2016 (aRR 1.6; 95% CI 1.2–2.0 and aRR 1.4; 95% CI 1.1–1.8) and patients in ITFC had 2.5 times higher LTFU rates when coming from a lead-affected village. Conclusions Our data contributes clearer understanding of the situation in the paediatric wards in AGH in Nigeria, but identifying specific predictors for the multifaceted nature of mortality and LTFU is challenging. Mortality in paediatric patients in IPD of AGH improved during the study period, which is likely linked to better awareness of the hospital, but still remains high. Access to healthcare due to seasonal restrictions contributes to mortalities due to late presentation. Increased awareness of and easier access to healthcare, such as for patients living in lead-affected villages, which are still benefiting from an MSF lead poisoning intervention, decreases mortalities, but increases LTFU. We recommend targeted case audits and qualitative studies to better understand the role of health-seeking behaviour, and social and traditional factors in the use of formal healthcare in this part of Nigeria and potentially similar settings in other countries.
- Published
- 2021
25. The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre
- Author
-
Delorme, Cécile, Houot, Marion, Rosso, Charlotte, Carvalho, Stéphanie, Nedelec, Thomas, Maatoug, Redwan, Pitron, Victor, Gassama, Salimata, Sambin, Sara, Bombois, Stéphanie, Herlin, Bastien, Ouvrard, Gaëlle, Bruneteau, Gaëlle, Hesters, Adèle, Gales, Ana Zenovia, Millet, Bruno, Lamari, Foudil, Lehericy, Stéphane, Navarro, Vincent, Rohaut, Benjamin, Demeret, Sophie, Maisonobe, Thierry, Yger, Marion, Degos, Bertrand, Mariani, Louise-Laure, Bouche, Christophe, Dzierzynski, Nathalie, Oquendo, Bruno, Ketz, Flora, Nguyen, An-Hung, Kas, Aurélie, Lubetzki, Catherine, Delattre, Jean-Yves, Corvol, Jean-Christophe, Fontaine, Bertrand, Thoumie, Philippe, Sharshar, Tarek, Alamowitch, Sonia, Apartis-Bourdieu, Emmanuelle, Peretti, Charles-Siegried, Ursu, Renata, Bourron, Kiyoka Kinugawa, Belmin, Joel, Pautas, Eric, Verny, Marc, Samson, Yves, Leder, Sara, Leger, Anne, Deltour, Sandrine, Baronnet, Flore, Touat, Mehdi, Sanson, Marc, Dehais, Caroline, Houillier, Caroline, Laigle-Donadey, Florence, Psimaras, Dimitri, Alenton, Agusti, Younan, Nadia, Villain, Nicolas, Del Mar Amador, Maria, Mezouar, Nicolas, Mangone, Graziella, Meneret, Aurelie, Hartmann, Andreas, Tarrano, Clement, Bendetowicz, David, Pradat, Pierre-François, Baulac, Michel, Pichit, Phintip, Chochon, Florence, Nguyen, An Hung, Porcher, Valerie, Demoule, Alexandre, Morawiec, Elise, Mayaux, Julien, Faure, Morgan, Ewenczyk, Claire, Coarelli, Giulia, Heinzmann, Anna, Masingue, Marion, Bassez, Guillaume, An, Isabelle, Worbe, Yulia, Lambrecq, Virginie, Debs, Rabab, Musat, Esteban Munoz, Lenglet, Timothee, Hanin, Aurelie, Chougar, Lydia, Shor, Nathalia, Pyatigorskaya, Nadya, Galanaud, Damien, Leclercq, Delphine, Cao, Albert, Marois, Clemence, Weiss, Nicolas, Le Guennec, Loic, Degos, Vincent, Jacquens, Alice, Similowski, Thomas, Morelot-Panzini, Capucine, Rotge, Jean-Yves, Saudreau, Bertrand, Sarni, Nassim, Girault, Nathalie, Leu, Smaranda, Thivard, Lionel, Mokhtari, Karima, Plu, Isabelle, Gonçalves, Bruno, Bottin, Laure, Haddad, Rebecca, Lafuente, Carmelo, Oasi, Christel, Megabarne, Bruno, Herve, Dominique, Salman, Haysam, Rametti-Lacroux, Armelle, Chalançon, Alize, Herve, Anais, Royer, Hugo, Beauzor, Florence, Maheo, Valentine, Laganot, Christelle, Minelli, Camille, Fekete, Aurelie, Grine, Abel, Biet, Marie, Hilab, Rania, Besnard, Aurore, Bouguerra, Meriem, Goudard, Gwen, Houairi, Saida, Al-Youssef, Saba, Pires, Christine, Oukhedouma, Anissa, Siuda-Krzywicka, Katarzyna, Malkinson, Tal Seidel, Agguini, Hanane, Said, Safia, Gales, Ana, Brochard, Vanessa, Bourron, Kiyoka, Nguyen, An, Musat, Esteban, Malkinson, Tal, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de psychiatrie adulte [CHU Pitié-Salpêtière], CHU Pitié-Salpêtrière [AP-HP], Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] (IM2A), Sorbonne Université (SU), Hôpital Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche en Myologie – U974 SU-INSERM, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service des Pathologies du sommeil [CHU Pitié-Salpêtrière], Service de Biochimie Métabolique [CHU Pitié-Salpêtrière], Service de Neuroradiologie [CHU Pitié-Salpêtrière], Service de Neurophysiologie [CHU Pitié-Salpêtrière], Service des Soins Intensifs [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Gériatrique [CHU Pitié-Salpêtrière], Service d'Activités cliniques [CHU Pitié-Salpêtrière], Service de médecine nucléaire [CHU Pitié-Salpétrière], Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Centre de Recherche en Myologie, and Service de gériatrie [CHU Pitié-Salpêtrière]
- Subjects
Pediatrics ,medicine.medical_specialty ,encephalitis ,Encephalopathy ,Context (language use) ,law.invention ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,law ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Intensive care ,medicine ,Critical illness polyneuropathy ,Biological Psychiatry ,030304 developmental biology ,0303 health sciences ,business.industry ,AcademicSubjects/SCI01870 ,COVID-19 ,medicine.disease ,encephalopathy ,Comorbidity ,Intensive care unit ,3. Good health ,Psychiatry and Mental health ,Neurology ,Observational study ,Original Article ,AcademicSubjects/MED00310 ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,business ,critical illness neuropathy ,030217 neurology & neurosurgery ,Encephalitis - Abstract
A variety of neuropsychiatric complications has been described in association with Covid-19 infection. Large scale studies presenting a wider picture of these complications and their relative frequency are lacking. The objective of our study was to describe the spectrum of neurological and psychiatric complications in patients with Covid-19 seen in a multidisciplinary hospital center over six months. We conducted a retrospective, observational study on all patients showing neurological or psychiatric symptoms in the context of Covid-19 seen in the medical and university neuroscience department of Assistance Publique Hopitaux de Paris -Sorbonne University. We collected demographic data, comorbidities, symptoms and severity of Covid-19 infection, neurological and psychiatric symptoms, neurological and psychiatric examination data and, when available, results from CSF analysis, MRI, EEG and EMG. A total of 249 Covid-19 patients with a de novo neurological or psychiatric manifestation were included in the database and 245 were included in the final analyses. One-hundred fourteen patients (47%) were admitted to the intensive care unit and 10 (4%) died. The most frequent neuropsychiatric complications diagnosed were encephalopathy (43%), critical illness polyneuropathy and myopathy (26%), isolated psychiatric disturbance (18%), and cerebrovascular disorders (16%). No patients showed CSF evidence of SARS-CoV-2. Encephalopathy was associated with older age and higher risk of death. Critical illness neuromyopathy was associated with an extended stay in the intensive care unit. The majority of these neuropsychiatric complications could be imputed to critical illness, intensive care and systemic inflammation, which contrasts with the paucity of more direct SARS-CoV-2-related complications or post-infection disorders., Graphical Abstract Graphical Abstract
- Published
- 2021
- Full Text
- View/download PDF
26. White matter microstructure in Parkinson’s disease with and without elevated REM sleep muscle tone
- Author
-
Michael J. Howell, Paul J. Tuite, E. Holker, Aleksandar Videnovic, Matthew N. Petrucci, J. De Kam, Jae Woo Chung, Maria E. Linn-Evans, Remi Patriat, Christophe Lenglet, Sommer L Amundsen-Huffmaster, Pramod Kumar Pisharady, Colum D. MacKinnon, and Noam Harel
- Subjects
medicine.medical_specialty ,Parkinson's disease ,medicine.diagnostic_test ,business.industry ,Eye movement ,Polysomnography ,Audiology ,medicine.disease ,Corpus callosum ,Sleep in non-human animals ,White matter ,Muscle tone ,medicine.anatomical_structure ,Fractional anisotropy ,medicine ,business - Abstract
The mechanisms contributing to increased expression of motor and cognitive impairment in people with Parkinson9s disease who lack muscle atonia during rapid eye movement (REM) sleep compared to those with muscle atonia are poorly understood. This study used tract-based spatial statistics to compare diffusion measures of white matter microstructure between people with Parkinson9s disease with and without REM sleep without atonia as well as the relationships of these measures to motor and cognitive function. Thirty-eight individuals with mild-to-moderate Parkinson9s disease and twenty-one matched control subjects underwent ultra-high-field MRI (7Tesla), quantitative motor assessments of gait and bradykinesia, and neuropsychological testing. The Parkinson9s disease cohort was separated post-hoc into those with and without elevated chin or leg muscle activity during REM sleep based on polysomnography findings. Fractional anisotropy was significantly higher, and radial and mean diffusivity significantly lower, in diffuse regions of the corpus callosum, projection, and association white matter pathways in the Parkinson9s group with normal REM sleep compared to controls. In contrast, there was no significant difference in fractional anisotropy between the Parkinson9s group with elevated muscle tone and controls. Fractional anisotropy was also significantly higher in a subset of pathways in the Parkinson9s disease group with normal REM sleep muscle tone compared to those with elevated REM sleep muscle tone. The group with elevated REM sleep muscle tone had significant impairments in gait and upper arm speed compared to controls and significantly worse scores in specific cognitive domains (executive function, visuospatial memory) compared to the Parkinson9s disease group with normal REM sleep muscle tone. Regression analyses showed that gait speed and step length in the Parkinson9s disease cohort were predicted by measures of mean fractional anisotropy of the anterior corona radiata, whereas elbow flexion velocity was predicted by fractional anisotropy of the superior corona radiata. Visuospatial memory task performance was predicted by the radial diffusivity of the posterior corona radiata. These findings demonstrate that people with mild-to-moderate severity of Parkinson9s disease who have normal muscle tone during REM sleep show alterations in white matter microstructure that are associated with preserved motor and cognitive function, but these adaptations are reduced or absent in those with increased REM sleep motor tone.
- Published
- 2021
- Full Text
- View/download PDF
27. Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer
- Author
-
Virginie Lucas, Mathieu Boone, Céline Bihan, Aurelie Lenglet, Aurelie Feral, Bruno Chauffert, and Mohamed Belhout
- Subjects
medicine.medical_specialty ,business.industry ,Cancer ,Antineoplastic Agents ,medicine.disease ,Pharmacists ,Medication Adherence ,Medication possession ratio ,Oncology ,Multidisciplinary approach ,Family medicine ,Neoplasms ,Medicine ,Humans ,Pharmacology (medical) ,In patient ,business ,Referral and Consultation ,Retrospective Studies - Abstract
Purpose To evaluate adherence (as measured by the medication possession ratio) to the first ever course of oral antineoplasic treatment in cancer patients before and after the implementation of a multidisciplinary consultation program (involving an oncologist, a pharmacist, and a nurse) and to investigate the program's impact on adverse events and drug-related problems. Patients and Methods In a retrospective single-center study, we compared the medication possession ratio 2 months after treatment initiation in a control group (before multidisciplinary consultation program implementation) versus an interventional group (after multidisciplinary consultation program implementation). Results Two months after oral antineoplasic treatment initiation, the mean ± standard deviation medication possession ratio did not differ significantly when comparing the interventional (multidisciplinary consultation program) group ( n = 33; 0.99 ± 0.06) with the control group ( n = 64; 0.94 ± 0.16) ( p = 0.062). Patients in the multidisciplinary consultation program group had fewer adverse events in general (41, vs 109 in the control group; p = 0.048) and digestive adverse events in particular (6 vs 29, respectively; p = 0.007). A total of 53 and 40 drug-related problems were identified in the control and multidisciplinary consultation program groups, respectively ( p = 0.074). Conclusions Implementation of an multidisciplinary consultation program was not associated with a significant difference in drug adherence (as assessed by the medication possession ratio), which was good before and after implementation. The multidisciplinary consultation program was associated with a lower incidence of adverse events.
- Published
- 2021
28. Hypertrophie gingivale et amlodipine, cas clinique
- Author
-
A. Durand, M. Belhout, L. Yang, G. Deschasse, F. Bloch, and A. Lenglet
- Subjects
business.industry ,Medicine ,Pharmacology (medical) ,business - Published
- 2020
- Full Text
- View/download PDF
29. A juvenile ALS‐like phenotype dramatically improved after high‐dose riboflavin treatment
- Author
-
François Salachas, Alice Veauville-Merllié, Cécile Acquaviva, Isabelle Mosnier, Timothée Lenglet, Yann Nadjar, Nicolas Weiss, Ghizlene Lahlou, Sophie Demeret, Christophe Carreau, Guillaume Fargeot, Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Neurophysiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Unité d’Otologie, implants auditifs et chirurgie de la base du crâne [CHU Pitié-Salpêtrière], Service d'Oto-Rhino-Laryngologie [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP]
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Adolescent ,Juvenile amyotrophic lateral sclerosis ,Hearing loss ,Hearing Loss, Sensorineural ,Riboflavin ,[SDV]Life Sciences [q-bio] ,Bulbar Palsy, Progressive ,Auditory neuropathy ,Neurosciences. Biological psychiatry. Neuropsychiatry ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Age of Onset ,Motor Neuron Disease ,RC346-429 ,Mutation ,Case Study ,business.industry ,General Neuroscience ,Amyotrophic Lateral Sclerosis ,Membrane Transport Proteins ,Motor neuron ,medicine.disease ,Phenotype ,030104 developmental biology ,Endocrinology ,medicine.anatomical_structure ,Respiratory failure ,Vitamin B Complex ,Female ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,medicine.symptom ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,030217 neurology & neurosurgery ,RC321-571 - Abstract
International audience; Riboflavin transporter deficiency (RTD) was recently characterized as a cause of genetic recessive childhood-onset motor neuron disease (MND) with hearing loss, formerly described as Brown-Vialetto-Van-Lear syndrome. We describe a 18-year-old woman with probable RTD mimicking juvenile Amyotrophic Lateral Sclerosis (ALS) who presented with an inaugural respiratory failure and moderate distal four limbs weakness. Only one heterozygous SLC52A3 mutation was detected, but presence of a sub-clinical auditory neuropathy and dramatic improvement under high dose riboflavin argued for a RTD. As RTD probably has a larger phenotypic spectrum than expected, a high dose riboflavin trial should be discussed in young-onset MND.
- Published
- 2020
- Full Text
- View/download PDF
30. Rectal screening displays high negative predictive value for bloodstream infection with (ESBL-producing) Gram-negative bacteria in neonates with suspected sepsis in a low-resource setting neonatal care unit
- Author
-
Michiel Lekkerkerker, Marine Berthet, Cono Ariti, Kessiane Charles, Joost Hopman, Collette Badjo, Heiman F. L. Wertheim, Annick Lenglet, Emily Borgundvaag, Rodnie Senat-Delva, Melissa McRae, Estiver Evens, Kate Clezy, and Jorien Schuurmans
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Gram-negative bacteria ,Concordance ,030106 microbiology ,Immunology ,Predictive value ,Bacteremia ,Microbiology ,Gastroenterology ,beta-Lactamases ,Sepsis ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Neonate ,0302 clinical medicine ,Predictive Value of Tests ,Internal medicine ,Gram-Negative Bacteria ,medicine ,Immunology and Allergy ,Humans ,Blood culture ,030212 general & internal medicine ,Rectal swab ,biology ,Neonatal sepsis ,medicine.diagnostic_test ,business.industry ,Infant, Newborn ,Outbreak ,Klebsiella oxytoca ,Late-onset sepsis ,biology.organism_classification ,medicine.disease ,Haiti ,QR1-502 ,Confidence interval ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,business ,Gram-Negative Bacterial Infections - Abstract
Objectives\ud\udWe analysed the concordance of rectal swab isolates and blood culture for Gram-negative bacteria (GNB) isolates in neonates with a suspicion of neonatal sepsis admitted to a neonatal care unit in Haiti.\udMethods\ud\udWe matched pairs of blood and rectal samples taken on the date of suspected sepsis onset in the same neonate. We calculated the proportion of rectal isolates in concordance with the blood isolates by species and genus. We calculated the negative predictive value (NPV) for GNB and extended-spectrum β-lactamase (ESBL)-producing GNB for all rectal and blood isolate pairs in neonates with suspected sepsis.\udResults\ud\udWe identified 238 blood and rectal samples pairs, with 238 blood isolate results and 309 rectal isolate results. The overall concordance in genus and species between blood and rectal isolates was 22.3% [95% confidence interval (CI) 17.4–28.0%] and 20.6% (95% CI 16.0–26.2%), respectively. The highest concordance between blood and rectal isolates was observed for samples with no bacterial growth (65%), followed byKlebsiella pneumoniae (18%) and Klebsiella oxytoca (12%). The NPV of detecting GNB bacterial isolates in rectal samples compared with those in blood samples was 81.6% and the NPV for ESBL-positive GNB was 92.6%.\udConclusions\ud\udThe NPV of rectal swab GNB isolates was high in all patient groups and was even higher for ESBL-positive GNB. Clinicians can use the results from rectal swabs when taken simultaneously with blood samples during outbreaks to inform the (de-)escalation of antibiotic therapy in those neonates that have an ongoing sepsis profile.
- Published
- 2020
- Full Text
- View/download PDF
31. ‘I treat it but I don’t know what this disease is’: a qualitative study on noma (cancrum oris) and traditional healing in northwest Nigeria
- Author
-
Julita Gil Cuesta, Adolphe Fotso, Annette de Jong, Ushma Mehta, Hussaina Muhammad Bala, Karla Bil, Annick Lenglet, Joseph Samuel, Bukola Oluyide, Emilie Venables, Nura Abubakar, Elise Farley, and Beverley Stringer
- Subjects
Adult ,Male ,Health Knowledge, Attitudes, Practice ,medicine.medical_specialty ,Health (social science) ,Referral ,Health Personnel ,education ,030231 tropical medicine ,Nigeria ,Noma ,Disease ,Young Adult ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Intervention (counseling) ,cancrum oris ,Health care ,Humans ,Medicine ,030212 general & internal medicine ,Child ,Medicine, African Traditional ,Referral and Consultation ,Qualitative Research ,business.industry ,Mortality rate ,Public Health, Environmental and Occupational Health ,Infant ,operational research ,Original Articles ,General Medicine ,Middle Aged ,medicine.disease ,traditional healers ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Child, Preschool ,traditional healing ,Family medicine ,Female ,Thematic analysis ,business ,Qualitative research - Abstract
BackgroundNoma, a neglected disease mostly affecting children, with a 90% mortality rate if untreated, is an orofacial gangrene that disintegrates the tissues of the face in MethodsWe conducted 12 in-depth interviews with caretakers who were looking after noma patients admitted at the Noma Children's Hospital and 15 traditional healers in their home villages in Sokoto state, northwest Nigeria. We explored perceptions of noma, relationship dynamics, healthcare practices and intervention opportunities. Interviews were audiorecorded, transcribed and translated. Manual coding and thematic analysis were utilised.ResultsTraditional healers offered specialised forms of care for specific conditions and referral guidance. They viewed the stages of noma as different conditions with individualised remedies and were willing to refer noma patients. Caretakers trusted traditional healers.ConclusionsTraditional healers could play a crucial role in the early detection of noma and the health-seeking decision-making process of patients. Intervention programmes should include traditional healers through training and referral partnerships. This collaboration could save lives and reduce the severity of noma complications.
- Published
- 2019
- Full Text
- View/download PDF
32. Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease
- Author
-
Sabrina Poirot-Leclercq, Carine Avondo, Maryam Assem, Gaëlle Lenglet, Lucie Hénaut, Gabriel Choukroun, Saïd Kamel, Ziad A. Massy, Jean-Marc Chillon, Cédric Boudot, Agnès Boullier, Maria Grissi, and François Brazier
- Subjects
0301 basic medicine ,medicine.medical_treatment ,Interleukin-1beta ,lcsh:Medicine ,Apoptosis ,Severity of Illness Index ,Brain Ischemia ,Mice ,0302 clinical medicine ,lcsh:Science ,Stroke ,Chemokine CCL2 ,Neurons ,Kidney ,Muscle Weakness ,Multidisciplinary ,Microglia ,NF-kappa B ,Nephrectomy ,medicine.anatomical_structure ,Cardiology ,Female ,Stroke recovery ,Neuroglia ,medicine.medical_specialty ,Kidney Cortex ,Rotarod performance test ,03 medical and health sciences ,Antigens, CD ,Internal medicine ,Severity of illness ,Electrocoagulation ,medicine ,Animals ,Humans ,Renal Insufficiency, Chronic ,Interleukin-6 ,business.industry ,Adenylate Kinase ,lcsh:R ,medicine.disease ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,Gene Expression Regulation ,Rotarod Performance Test ,lcsh:Q ,business ,030217 neurology & neurosurgery ,Kidney disease - Abstract
Ischemic stroke is highly prevalent in chronic kidney disease (CKD) patients and has been associated with a higher risk of neurological deterioration and in-hospital mortality. To date, little is known about the processes by which CKD worsens ischemic stroke. This work aimed to investigate the cellular and molecular mechanism associated with ischemic stroke severity in an in vivo model of CKD. CKD was induced through right kidney cortical electrocautery in 8-week-old female C57BL/6 J mice followed by left total nephrectomy. Transient middle cerebral artery occlusion (tMCAO) was performed 6 weeks after left nephrectomy. Twenty-four hours after tMCAO, the infarct volumes were significantly wider in CKD than in SHAM mice. CKD mice displayed decreased neuroscore, impaired ability to remain on rotarod device, weaker muscular strength and decreased prehensile score. Apoptosis, neuronal loss, glial cells recruitment and microglia/macrophages M1 signature genes CD32, CD86, IL-1β, IL-6, MCP1 and iNOS were significantly increased within ischemic lesions of CKD mice. This effect was associated with decreased AMP kinase phosphorylation and increased activation of the NFΚB pathway. Pharmacological targeting of AMP kinase activity, which is known to block microglia/macrophages M1 polarization, appears promising to improve stroke recovery in CKD.
- Published
- 2019
- Full Text
- View/download PDF
33. Activation of the calcium-sensing receptor in human valvular interstitial cells promotes calcification
- Author
-
Lucie Hénaut, Cédric Boudot, Aida Ibrik, Thierry Caus, Michel Brazier, Romuald Mentaverri, Hawraa Issa, Saïd Kamel, Carine Avondo, Jeanne Bou Abdallah, Gaëlle Lenglet, Kazem Zibara, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, and CHU Amiens-Picardie
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Calcification inhibitor ,Calcimimetic ,[SDV]Life Sciences [q-bio] ,Down-Regulation ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Osteogenesis ,Internal medicine ,medicine ,Cardiac valve calcification ,Humans ,Osteopontin ,Receptor ,Molecular Biology ,ComputingMilieux_MISCELLANEOUS ,Minerals ,biology ,Chemistry ,Calcinosis ,Aortic Valve Stenosis ,medicine.disease ,3. Good health ,030104 developmental biology ,Endocrinology ,Aortic Valve ,Calcilytic ,biology.protein ,Calcium ,Tricuspid Valve ,Calcium-sensing receptor ,Cardiology and Cardiovascular Medicine ,Receptors, Calcium-Sensing ,Calcification - Abstract
Introduction and aims Calcific aortic valve disease (CAVD) is the most common heart valve disease in western countries. It has been reported that activation of the calcium-sensing receptor(CaSR) expressed by vascular smooth muscle cells prevents vascular calcification. However, to date, the CaSR's expression and function in cardiac valves have not been studied. The present study sought to evaluate the presence of the CaSR within human valvular interstitial cells (hVICs), assess the CaSR's functionality, and ascertain its involvement in hVIC calcification. Methods and results Data from Western blot, flow cytometry and immunocytochemistry experiments demonstrated that primary hVICs express the CaSR. The receptor was functional, since the incubation of hVICs with the calcimimetic R-568 significantly increased Ca2+-induced ERK1/2 phosphorylation, and exposure to the calcilytic NPS2143 reduced ERK1/2 activation. A reduction in endogenous CaSR expression by hVICs (using siRNA) was associated with significantly lower levels of Ca2+-induced mineralization (quantified using Alizarin Red staining). Similar data were obtained after the pharmacological inhibition of CaSR activity by the calcilytic NPS2143. In contrast, overexpression of a functional CaSR amplified Ca2+-induced calcification. Pharmacological activation of the CaSR with the calcimimetic R-568 showed similar effects. CaSR's procalcific properties are associated with increased osteogenic transition (as characterized by elevated mRNA expression of bone morphogenetic protein 2 and osterix), and reduced the expression of the calcification inhibitor osteopontin. Histological analysis of 12 human aortic tricuspid valves showed that CaSR expression was greater in calcified areas than in non-calcified areas. These data were confirmed by Western blots. Conclusions To the best of our knowledge, this study is the first to have demonstrated that hVICs express a functional CaSR. Taken as a whole, our data suggest that activation of the CaSR expressed by hVICs might be a key promoter of CAVD progression.
- Published
- 2019
- Full Text
- View/download PDF
34. Functional Magnetic Resonance Imaging and Oculomotor Dysfunction in Mild Traumatic Brain Injury
- Author
-
Gaylan L. Rockswold, Walter C. Low, Essa Yacoub, Andrea Grant, Philip C. Burton, Nova McNally, Christophe Lenglet, Amy Chang, Sarah B. Rockswold, and Lynn E. Eberly
- Subjects
Adult ,Male ,030506 rehabilitation ,medicine.medical_specialty ,Eye Movements ,Traumatic brain injury ,Brain activity and meditation ,Neuropsychological Tests ,Audiology ,Cuneus ,Lingual gyrus ,03 medical and health sciences ,Ocular Motility Disorders ,0302 clinical medicine ,Humans ,Medicine ,Prospective Studies ,Brain Concussion ,Blood-oxygen-level dependent ,medicine.diagnostic_test ,Resting state fMRI ,business.industry ,Functional Neuroimaging ,Brain ,Original Articles ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,Female ,Neurology (clinical) ,0305 other medical science ,business ,Functional magnetic resonance imaging ,030217 neurology & neurosurgery ,Parahippocampal gyrus ,Spatial Navigation - Abstract
Mild traumatic brain injury (mTBI) is a significant cause of disability, especially when symptoms become chronic. This chronicity is often linked to oculomotor dysfunction (OMD). To our knowledge, this is the first prospective study to localize aberrations in brain function between mTBI cohorts, by comparing patients with mTBI with OMD with an mTBI control group without OMD, using task and resting-state functional magnetic resonance imaging (fMRI). Ten subjects with mTBI who had OMD (OMD group) were compared with nine subjects with mTBI who had no findings of OMD (control group). These groups were determined by a developmental optometrist using objective testing for OMD. The (convergence) task fMRI data demonstrated significantly decreased brain activity, measured as decreases in the blood oxygen level dependent (BOLD) signal, in the OMD group compared with the control group in three brain regions: the left posterior lingual gyrus, the bilateral anterior lingual gyrus and cuneus, and the parahippocampal gyrus. When doing a seed-based resting state fMRI analysis in the lingual/parahippocampal region, a large cluster covering the left middle frontal gyrus and the dorsolateral pre-frontal cortex (Brodmann areas 9 and 10), with decreased functional correlation in the OMD group, was identified. Together these observations provide evidence for neural networks of interactions involving the control of eye movement for visual processing, reading comprehension, spatial localization and navigation, and spatial working memory that appear to be decreased in mTBI patients with OMD compared with mTBI patients without OMD. The clinical symptomatology associated with post-traumatic OMD correlates well with these MRI findings.
- Published
- 2019
- Full Text
- View/download PDF
35. Effect of SSRIs on Resting-State Functional Brain Networks in Adolescents with Major Depressive Disorder
- Author
-
Bryon A. Mueller, Shu-Hsien Chu, Christophe Lenglet, Bonnie Klimes-Dougan, Melinda Westlund Schreiner, Keshab K. Parhi, and Kathryn R. Cullen
- Subjects
major depressive disorder (MDD) ,functional magnetic resonance imaging (fMRI) ,resting-state functional connectivity (RSFC) ,frequency-dependent connectivity ,network topology ,medicine.diagnostic_test ,Resting state fMRI ,business.industry ,Putamen ,Serotonin reuptake inhibitor ,General Medicine ,medicine.disease ,Article ,Superior temporal gyrus ,medicine ,Major depressive disorder ,Middle frontal gyrus ,Medicine ,Functional magnetic resonance imaging ,business ,Neuroscience ,Default mode network - Abstract
Investigation of brain changes in functional connectivity and functional network topology from receiving 8-week selective serotonin reuptake inhibitor (SSRI) treatments is conducted in 12 unmedicated adolescents with major depressive disorder (MDD) by using wavelet-filtered resting-state functional magnetic resonance imaging (fMRI). Changes are observed in frontal-limbic, temporal, and default mode networks. In particular, topological analysis shows, at the global scale and in the 0.12–0.25 Hz band, that the normalized clustering coefficient and smallworldness of brain networks decreased after treatment. Regional changes in clustering coefficient and efficiency were observed in the bilateral caudal middle frontal gyrus, rostral middle frontal gyrus, superior temporal gyrus, left pars triangularis, putamen, and right superior frontal gyrus. Furthermore, changes of nodal centrality and changes of connectivity associated with these frontal and temporal regions confirm the global topological alternations. Moreover, frequency dependence is observed from FDR-controlled subnetworks for the limbic-cortical connectivity change. In the high-frequency band, the altered connections involve mostly frontal regions, while the altered connections in the low-frequency bands spread to parietal and temporal areas. Due to the limitation of small sample sizes and lack of placebo control, these preliminary findings require confirmation with future work using larger samples. Confirmation of biomarkers associated with treatment could suggest potential avenues for clinical applications such as tracking treatment response and neurobiologically informed treatment optimization.
- Published
- 2021
36. Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers
- Author
-
Alexandra Tinnermann, Dimitri Van De Ville, Cornelia Laule, Sean Mackey, Robert L. Barry, Benjamin De Leener, Anna Pichiecchio, Eva Alonso-Ortiz, Giancarlo Germani, Ali Khatibi, Nico Papinutto, Marc J. Ruitenberg, René Labounek, Nawal Kinany, Francesco Grussu, Michela Fratini, Petr Kudlička, Christophe Lenglet, Kouhei Kamiya, Pierre-Gilles Henry, Julien Cohen-Adad, Richard G. Wise, Deborah Pareto, Tomáš Horák, Jürgen Finsterbusch, Alex Rovira, Todd B. Parrish, Y. Suzuki, George Tackley, Junqian Xu, Falk Eippert, Virginie Callot, Daniel Papp, Laura Barlow, Karla R. Epperson, Charley Gros, Nicole Atcheson, Akifumi Hagiwara, Jan Valošek, Yaou Liu, Patrick Freund, Maria Marcella Laganà, James M. Joers, Marco Battiston, Markus Barth, Adam V. Dvorak, Masaaki Hori, Joo Won Kim, Miloš Keřkovský, Paulo Loureiro de Sousa, Sara Llufriu, Mihael Abramovic, Igor Nestrasil, Kenneth A. Weber, Christine S. Law, Paul Kuntke, Elisabeth Solana, Kristin P. O’Grady, Alexandru Foias, Slawomir Kusmia, Claudia A. M. Wheeler-Kingshott, Hagen H. Kitzler, Alex K. Smith, Nyoman D. Kurniawan, Shannon H. Kolind, Marios C. Yiannakas, Seth A. Smith, Zachary A. Smith, Federico Giove, Tobias Leutritz, Matthew D. Budde, Rebecca S. Samson, Christian Büchel, Kevin S. Epperson, Marek Dostál, Giovanni Savini, Issei Fukunaga, Haleh Karbasforoushan, Loan Mattera, Nikolaus Weiskopf, Guillaume Gilbert, Yazhuo Kong, Ferran Prados, Maryam Seif, Anna J.E. Combes, Julien Doyon, P Wyss, Alan C. Seifert, Carina Arneitz, Eloy Martinez-Heras, Maxime Descoteaux, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - AP-HM] (CEMEREM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Universitat Oberta de Catalunya (UOC), Universitat Oberta de Catalunya. eHealth Center, Institut Català de la Salut, [Cohen-Adad J] NeuroPoly Lab, Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC, Canada. Functional Neuroimaging Unit, CRIUGM, Université de Montréal, Montreal, QC, Canada. Mila - Quebec AI Institute, Montreal, QC, Canada. [Alonso-Ortiz E] NeuroPoly Lab, Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC, Canada. [Abramovic M, Arneitz C] Department of Radiology, Swiss Paraplegic Centre, Nottwil, Switzerland. [Atcheson N] Centre for Advanced Imaging, The University of Queensland, Brisbane, Australia. [Barlow L] Department of Radiology, University of British Columbia, Vancouver, BC, Canada. [Grussu F] NMR Research Unit, Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. Radiomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pareto D, Rovira À] Secció de Neuroradiologia, Vall d’Hebron Hospital Universitri, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] (CEMEREM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, and Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Statistics and Probability ,Data Descriptor ,medicine.medical_specialty ,Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] ,Investigació - Avaluació ,Nervous System::Central Nervous System::Spinal Cord [ANATOMY] ,databases ,Computer science ,Science ,of-the-art ,Spinal cord diseases ,Spinal Cord Diseases ,Imaging techniques ,Library and Information Sciences ,030218 nuclear medicine & medical imaging ,Education ,Databases ,03 medical and health sciences ,0302 clinical medicine ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Reproducibility of Results [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,medicine ,Medical physics ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Protocol (science) ,Reproducibility ,Extramural ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,técnicas de investigación::métodos epidemiológicos::diseño de la investigación epidemiológica::reproducibilidad de los resultados [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,white ,Spinal cord ,spinal cord diseases ,Toolbox ,imaging techniques ,matter ,Computer Science Applications ,magnetization-transfer ,medicine.anatomical_structure ,Imatgeria per ressonància magnètica ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,sistema nervioso::sistema nervioso central::médula espinal [ANATOMÍA] ,Statistics, Probability and Uncertainty ,Medul·la espinal - Malalties - Imatgeria ,030217 neurology & neurosurgery ,Information Systems - Abstract
In a companion paper by Cohen-Adad et al. we introduce the spine generic quantitative MRI protocol that provides valuable metrics for assessing spinal cord macrostructural and microstructural integrity. This protocol was used to acquire a single subject dataset across 19 centers and a multi-subject dataset across 42 centers (for a total of 260 participants), spanning the three main MRI manufacturers: GE, Philips and Siemens. Both datasets are publicly available via git-annex. Data were analysed using the Spinal Cord Toolbox to produce normative values as well as inter/intra-site and inter/intra-manufacturer statistics. Reproducibility for the spine generic protocol was high across sites and manufacturers, with an average inter-site coefficient of variation of less than 5% for all the metrics. Full documentation and results can be found at https://spine-generic.rtfd.io/. The datasets and analysis pipeline will help pave the way towards accessible and reproducible quantitative MRI in the spinal cord., Measurement(s)spinal cordTechnology Type(s)magnetic resonance imagingFactor Type(s)manufacturer • siteSample Characteristic - OrganismHomo sapiensSample Characteristic - LocationCanada • Switzerland • Australia • United States of America • United Kingdom • Germany • French Republic • Czech Republic • Italy • Japan • Kingdom of Spain • China Machine-accessible metadata file describing the reported data: 10.6084/m9.figshare.14052269
- Published
- 2021
- Full Text
- View/download PDF
37. Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease
- Author
-
Maria Grissi, Jean-Marc Chillon, Gaëlle Lenglet, Mathilde Lando, Alexandre Candellier, Youssef Bennis, Ziad A. Massy, Lucie Hénaut, Maryam Assem, Carine Avondo, Saïd Kamel, Sabrina Poirot-Leclercq, Gabriel Choukroun, Agnès Boullier, Jean-Daniel Lalau, Cédric Boudot, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], and HAL UVSQ, Équipe
- Subjects
Brain Infarction ,medicine.medical_specialty ,Science ,[SDV]Life Sciences [q-bio] ,Urology ,Diseases ,Apoptosis ,urologic and male genital diseases ,Models, Biological ,Article ,Grip strength ,medicine ,Animals ,Gliosis ,Renal Insufficiency, Chronic ,Ischemic Preconditioning ,Stroke ,Neurons ,Kidney ,Multidisciplinary ,Microglia ,business.industry ,Macrophages ,Adenylate Kinase ,Body Weight ,NF-kappa B ,AMPK ,Infarction, Middle Cerebral Artery ,medicine.disease ,Metformin ,[SDV] Life Sciences [q-bio] ,Enzyme Activation ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Neurology ,Gene Expression Regulation ,Nephrology ,Medicine ,Female ,business ,Kidney disease ,medicine.drug - Abstract
Chronic kidney disease (CKD) worsens ischemic stroke severity in both patients and animals. In mice, these poorer functional outcomes are associated with decreased brain activity of AMP-activated protein kinase (AMPK), a molecule that recently emerged as a potential therapeutic target for ischemic stroke. The antidiabetic drug metformin, a well-known activator of AMPK, has improved stroke outcomes in diabetic patients with normal renal function. We investigated whether chronic metformin pre-conditioning can rescue AMPK activity and prevent stroke damage in non-diabetic mice with CKD. Eight-week-old female C57BL/6J mice were assigned to CKD or SHAM groups. CKD was induced through right kidney cortical electrocautery, followed by left total nephrectomy. Mice were then allocated to receive metformin (200 mg/kg/day) or vehicle for 5 weeks until stroke induction by transient middle cerebral artery occlusion (tMCAO). The infarct volumes were lower in CKD mice exposed to metformin than in vehicle-treated CKD mice 24 h after tMCAO. Metformin pre-conditioning of CKD mice improved their neurological score, grip strength, and prehensile abilities. It also enhanced AMPK activation, reduced apoptosis, increased neuron survival and decreased microglia/macrophage M1 signature gene expression as well as CKD-induced activation of the canonical NF-κB pathway in the ischemic lesions of CKD mice.
- Published
- 2021
- Full Text
- View/download PDF
38. Neuropathic pain, dysautonomia, and nerve hyperexcitability: Expanding the spectrum of LGI1 autoimmunity
- Author
-
Timothée Lenglet, Fleur Cohen, Dimitri Psimaras, Marine Giry, Giulia Berzero, Jacques d'Anglejan, Bastien Joubert, Berzero, G., Lenglet, T., Giry, M., D'Anglejan, J., Joubert, B., Cohen, F., and Psimaras, D.
- Subjects
business.industry ,Dysautonomia ,Bioinformatics ,medicine.disease_cause ,Sensory Systems ,Autoimmunity ,Neurology ,Physiology (medical) ,Proteins metabolism ,Neuropathic pain ,Medicine ,Neurology (clinical) ,medicine.symptom ,business - Published
- 2019
- Full Text
- View/download PDF
39. A Retrospective Analysis of 235 Patients and 281 Radiotherapy Plans for Sialorrhea Treatment in Amyotrophic Lateral Sclerosis and Parkinson Patients
- Author
-
A. Schernberg, Adèle Hesters, P.-F. Pradat, M. del Mar Amador, Jésus Gonzalez-Bermejo, T. Lenglet, Capucine Morélot-Panzini, Gaëlle Bruneteau, N. Le Forestier, François Salachas, Avi Assouline, and Sylvie Delanian
- Subjects
Cancer Research ,medicine.medical_specialty ,Radiation ,Sialorrhea ,business.industry ,medicine.medical_treatment ,Urology ,Neurological disorder ,medicine.disease ,Parotid gland ,SSS ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Refractory ,Toxicity ,medicine ,Radiology, Nuclear Medicine and imaging ,Amyotrophic lateral sclerosis ,business - Abstract
PURPOSE/OBJECTIVE(S) To evaluate the efficacy and safety of radiotherapy (RT) of the primary salivary glands in a large series of patients with amyotrophic lateral sclerosis (ALS) and Parkinson's disease with sialorrhea. MATERIALS/METHODS Patients treated in our institution between 2010 and 2020 were retrospectively analyzed, including the first 50 patients prospectively analyzed. All patients included were refractory to conventional sialorrhea drug treatments. RT was delivered by a conventional LINAC, with 2 opposite beams including the two submandibular glands and two thirds of the two parotid glands before 2014, and from 2015 2 lateral beams including the submaxillary glands, and 2 opposite oblique beams directed to each parotid gland, with reduced oral cavity irradiation. The total dose delivered was 10 Gy in 2 fractions or 20 Gy in 4 fractions. RT efficacy was assessed using the 9-item Sialorrhea Scoring Scale (SSS), prospectively validated as the most effective and sensitive tool for measuring sialorrhea in ALS patients. RESULTS A total of 235 patients were included, and 281 treatments (45 reirradiations, 1 patient received 3 irradiations). Median age was 69 years (range: 38 - 95), 127 women (54%) and 126 men (46%), 212 had ALS (90%), 17 had Parkinson's disease (7%), and 5 patients (3%) had another neurological disorder. Median interval between the first and second radiotherapy course was 7.5 months (range: 1 - 37). The median SSS score before radiation therapy was 8 (range: 6 - 9), and the median SSS score at 1 month of irradiation was 2 (range: 1 - 6). There was no toxicity of > grade 1. At the end of RT, all but one patient had an improvement in SSS score: 272 had a complete response (CR) (97%, SSS 1-3) and 8 had a partial response (PR) (3%, SSS 4-5); one patient had a stable SSS score (< 1%). A 1-month CR after RT was achieved in 96% of the 235 patients who underwent a primary RT, and 100% of the 45 patients who received re-irradiation. Patients treated with 20Gy versus 10Gy during the first RT treatment were more likely to have a CR at 1 month (99% vs. 91%, P = 0.007), and had a greater decrease in SSS score (mean difference -6 vs. -5 points, P < 0.001). Also, the 45 patients who received reirradiation were more frequently previously treated with the RT 10Gy protocol (25/45 patients, 55%) versus 60/191 (31%) in patients who did not require reirradiation (P < 0.001). The 3-beam irradiation technique, used from 2014 and beyond, did not significantly improve treatment efficacy (reduction of the SSS score by -5.8 points on average versus -5.6 points previously, P = 0.3). Nevertheless, it reduced 1 month toxicity, in particular decreased saliva thickening discomfort (P < 0.001). CONCLUSION A 20 Gy irradiation in 4 fractions is an effective treatment for ALS patients with sialorrhea, with minimal toxicity, particularly by separately targeting parotid and submaxillary glands. A shorter RT (10 Gy in 2 fractions) may be proposed in patients with poor medical condition, subject to its lower efficacy and the greater need for reirradiation.
- Published
- 2021
- Full Text
- View/download PDF
40. Growth and neurodevelopment in low birth weight versus normal birth weight infants from birth to 24 months, born in an obstetric emergency hospital in Haiti, a prospective cohort study
- Author
-
Cono Ariti, Kessiane Charles, Elizabeth Ledger, Lindsay Bryson, Rodnie Selva Denat, Daan Van Brusselen, Annick Lenglet, Xanthi D. Andrianou, Sonja Buitenhuis, Harriet Roggeveen, and Marjorie Hilaire
- Subjects
Pediatrics ,medicine.medical_specialty ,Birth weight ,Gross motor skill ,Bayley Scales of Infant Development ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Pregnancy ,030225 pediatrics ,medicine ,Birth Weight ,Humans ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,reproductive and urinary physiology ,business.industry ,Infant, Newborn ,lcsh:RJ1-570 ,Infant ,lcsh:Pediatrics ,Infant, Low Birth Weight ,Anthropometry ,medicine.disease ,Haiti ,Hospitals ,Low birth weight ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Pediatrics, Perinatology and Child Health ,Female ,medicine.symptom ,business ,Weight gain ,Research Article - Abstract
Background Low birthweight (LBW) infants are at higher risk of mortality and morbidity (growth, chronic disease and neurological problems) during their life. Due to the high incidence of (pre-) eclampsia in Haiti, LBW infants are common. We assessed the anthropometric growth (weight and length) and neurodevelopmental delay in LBW and normal birthweight (NBW) infants born at an obstetric emergency hospital in Port au Prince, Haiti, between 2014 and 2017. Methods Infants were followed at discharge and 3, 6, 12, 15, 18, 21 and 24 months of corrected gestational age. At each visit they underwent a physical checkup (weight, length, physical abnormalities, identification of morbidities). At 6, 12, 18 and 24 months they underwent a neurodevelopmental assessment using the Bayley Scale III (motor, cognitive and communication skills). We modelled the trajectories between birth and 24 months of age of NBW compared to LBW infants for weight, length, and raw scores for Bayley III assessments using mixed linear models. Results In total 500 LBW and 210 NBW infants were recruited of which 333 (46.7%) were followed up for 24 months (127 NBW; 60.5% and 206 LBW; 41.2%) and 150 died (LBW = 137 and NBW = 13). LBW and NBW babies gained a mean 15.8 g and 11.4 g per kg of weight from discharge per day respectively. The speed of weight gain decreased rapidly after 3 months in both groups. Both groups grow rapidly up to 6 months of age. LBW grew more than the NBW group during this period (22.8 cm vs. 21.1 cm). Both groups had WHZ scores Conclusion LBW babies that survive neonatal care in urban Haiti and live up to 24 months of age, perform similar to their NBW for weight, length and fine motor skills. LBW babies are delayed in gross motor, cognitive and communication skills development. Further research on the clinical significance of these findings and long term implications of this neurodevelopmental delay is needed.
- Published
- 2021
- Full Text
- View/download PDF
41. Diffusion magnetic resonance imaging reveals tract‐specific microstructural correlates of electrophysiological impairments in non‐myelopathic and myelopathic spinal cord compression
- Author
-
René Labounek, Tomáš Rohan, Josef Bednařík, Zdeněk Kadaňka, Miloš Keřkovský, Eva Vlčková, Magda Horáková, Alena Svátková, Petr Hluštík, Christophe Lenglet, Jan Valošek, Petr Bednařík, Julien Cohen-Adad, Jan Kočica, and Tomáš Horák
- Subjects
Pathology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,Sensory system ,Electromyography ,medicine.disease ,Asymptomatic ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Electrophysiology ,Myelopathy ,0302 clinical medicine ,Neurology ,Spinal cord compression ,medicine ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Diffusion MRI - Abstract
BACKGROUND AND PURPOSE Non-myelopathic degenerative cervical spinal cord compression (NMDC) frequently occurs throughout aging and may progress to potentially irreversible degenerative cervical myelopathy (DCM). Whereas standard clinical magnetic resonance imaging (MRI) and electrophysiological measures assess compression severity and neurological dysfunction, respectively, underlying microstructural deficits still have to be established in NMDC and DCM patients. The study aims to establish tract-specific diffusion MRI markers of electrophysiological deficits to predict the progression of asymptomatic NMDC to symptomatic DCM. METHODS High-resolution 3 T diffusion MRI was acquired for 103 NMDC and 21 DCM patients compared to 60 healthy controls to reveal diffusion alterations and relationships between tract-specific diffusion metrics and corresponding electrophysiological measures and compression severity. Relationship between the degree of DCM disability, assessed by the modified Japanese Orthopaedic Association scale, and tract-specific microstructural changes in DCM patients was also explored. RESULTS The study identified diffusion-derived abnormalities in the gray matter, dorsal and lateral tracts congruent with trans-synaptic degeneration and demyelination in chronic degenerative spinal cord compression with more profound alterations in DCM than NMDC. Diffusion metrics were affected in the C3-6 area as well as above the compression level at C3 with more profound rostral deficits in DCM than NMDC. Alterations in lateral motor and dorsal sensory tracts correlated with motor and sensory evoked potentials, respectively, whereas electromyography outcomes corresponded with gray matter microstructure. DCM disability corresponded with microstructure alteration in lateral columns. CONCLUSIONS Outcomes imply the necessity of high-resolution tract-specific diffusion MRI for monitoring degenerative spinal pathology in longitudinal studies.
- Published
- 2021
- Full Text
- View/download PDF
42. Multi-drug resistance and high mortality associated with community-acquired bloodstream infections in children in conflict-affected northwest Nigeria
- Author
-
Heiman F. L. Wertheim, Guy Maloba, Abiodun Egwuenu, Joost Hopman, Harriet Roggeveen, Cono Ariti, Frederick Chukwumeze, Mark Sherlock, Bukola Oluyide, Gbemisola Oloruntuyi, Chijioke Ikenna Nwankwo, Diana Gomez, Kate Clezy, Nwogu Ahamba Augustine, Annick Lenglet, Abdulhakeem Mohammed Lawal, Ruth Olubiyo, and Shoaib Muhammad
- Subjects
Male ,Methicillin-Resistant Staphylococcus aureus ,medicine.medical_specialty ,medicine.drug_class ,Epidemiology ,Science ,Antibiotics ,Nigeria ,Bacteremia ,Drug resistance ,Antimicrobial resistance ,Article ,Sepsis ,symbols.namesake ,Antibiotic resistance ,Drug Resistance, Multiple, Bacterial ,medicine ,Humans ,Blood culture ,Poisson regression ,Multidisciplinary ,medicine.diagnostic_test ,Bacteria ,business.industry ,Infant ,Staphylococcal Infections ,medicine.disease ,Anti-Bacterial Agents ,Community-Acquired Infections ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Child, Preschool ,Emergency medicine ,symbols ,Medicine ,Female ,business ,Malaria - Abstract
Contains fulltext : 244043.pdf (Publisher’s version ) (Open Access) Pediatric community-acquired bloodstream infections (CA-BSIs) in sub Saharan African humanitarian contexts are rarely documented. Effective treatment of these infections is additionally complicated by increasing rates of antimicrobial resistance. We describe the findings from epidemiological and microbiological surveillance implemented in pediatric patients with suspected CA-BSIs presenting for care at a secondary hospital in the conflict affected area of Zamfara state, Nigeria. Any child (> 2 months of age) presenting to Anka General Hospital from November 2018 to August 2020 with clinical severe sepsis at admission had clinical and epidemiological information and a blood culture collected at admission. Bacterial isolates were tested for antibiotic susceptibility. We calculated frequencies of epidemiological, microbiological and clinical parameters. We explored risk factors for death amongst severe sepsis cases using univariable and multivariable Poisson regression, adjusting for time between admission and hospital exit. We included 234 severe sepsis patients with 195 blood culture results. There were 39 positive blood cultures. Of the bacterial isolates, 14 were Gram positive and 18 were Gram negative; 5 were resistant to empiric antibiotics: methicillin-resistant Staphylococcus aureus (MRSA; n = 2) and Extended Spectrum Beta-Lactamase positive enterobacterales (n = 3). We identified no significant association between sex, age-group, ward, CA-BSI, appropriate intravenous antibiotic, malaria positivity at admission, suspected focus of sepsis, clinical severity and death in the multivariable regression. There is an urgent need for access to good clinical microbiological services, including point of care methods, and awareness and practice around rational antibiotic in healthcare staff in humanitarian settings to reduce morbidity and mortality from sepsis in children.
- Published
- 2021
43. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins?
- Author
-
Sophie Liabeuf, Griet Glorieux, Aurelie Lenglet, Momar Diouf, Eva Schepers, Lucie Desjardins, Gabriel Choukroun, Raymond Vanholder, Ziad A Massy, and European Uremic Toxin (EUTox) Work Group
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Uremic toxins are emerging as important, non-traditional cardiovascular risk factors in chronic kidney disease (CKD). P-cresol has been defined as a prototype protein-bound uremic toxin. Conjugation of p-cresol creates p-cresylsulfate (PCS) as the main metabolite and p-cresylglucuronide (PCG), at a markedly lower concentration. The objective of the present study was to evaluate serum PCG levels, determine the latter's association with mortality and establish whether the various protein-bound uremic toxins (i.e. PCS, PCG and indoxylsulfate (IS)) differed in their ability to predict mortality. METHODOLOGY/PRINCIPAL FINDINGS: We studied 139 patients (mean ± SD age: 67±12; males: 60%) at different CKD stages (34.5% at CKD stages 2-3, 33.5% at stage 4-5 and 32% at stage 5D). A recently developed high-performance liquid chromatography method was used to assay PCG concentrations. Total and free PCG levels increased with the severity of CKD. During the study period (mean duration: 779±185 days), 38 patients died. High free and total PCG levels were correlated with overall and cardiovascular mortality independently of well-known predictors of survival, such as age, vascular calcification, anemia, inflammation and (in predialysis patients) the estimated glomerular filtration rate. In the same cohort, free PCS levels and free IS levels were both correlated with mortality. Furthermore, the respective predictive powers of three Cox multivariate models (free PCS+other risk factors, free IS+other risk factors and free PCS+other risk factors) were quite similar--suggesting that an elevated PCG concentration has much the same impact on mortality as other uremic toxins (such as PCS or IS) do. CONCLUSIONS: Although PCG is the minor metabolite of p-cresol, our study is the first to reveal its association with mortality. Furthermore, the free fraction of PCG appears to have much the same predictive power for mortality as PCS and IS do.
- Published
- 2013
- Full Text
- View/download PDF
44. N-methyl-2-pyridone-5-carboxamide (2PY)—Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin
- Author
-
Aurélie Lenglet, Sophie Liabeuf, Sandra Bodeau, Loïc Louvet, Aurélien Mary, Agnès Boullier, Anne Sophie Lemaire-Hurtel, Alexia Jonet, Pascal Sonnet, Said Kamel, and Ziad A. Massy
- Subjects
N-methyl-2-pyridone-5-carboxamide ,uremic toxin ,nicotinamide ,niacin ,chronic kidney disease ,Medicine - Abstract
N-methyl-2-pyridone-5-carboxamide (2PY, a major metabolite of nicotinamide, NAM) was recently identified as a uremic toxin. Recent interventional trials using NAM to treat high levels of phosphorus in end-stage renal disease have highlighted new potential uremic toxicities of 2PY. In the context of uremia, the accumulation of 2PY could be harmful—perhaps by inhibiting poly (ADP-ribose) polymerase-1 activity. Here, we review recently published data on 2PY’s metabolism and toxicological profile.
- Published
- 2016
- Full Text
- View/download PDF
45. Brainstem and striatal volume changes are detectable in under 1 year and predict motor decline in spinocerebellar ataxia type 1
- Author
-
Timothy R. Koscik, Dinesh K. Deelchand, James M. Joers, Ellen van der Plas, Peggy Nopoulos, Lauren Sloat, Christophe Lenglet, and Gülin Öz
- Subjects
Pathology ,medicine.medical_specialty ,Spinocerebellar Ataxia Type 1 ,Cerebellum ,congenital, hereditary, and neonatal diseases and abnormalities ,motor disorders ,03 medical and health sciences ,0302 clinical medicine ,spinocerebellar ataxia ,medicine ,030304 developmental biology ,volumetry ,0303 health sciences ,medicine.diagnostic_test ,business.industry ,AcademicSubjects/SCI01870 ,Putamen ,General Engineering ,biomarkers ,Magnetic resonance imaging ,medicine.disease ,Pons ,medicine.anatomical_structure ,Brain size ,Spinocerebellar ataxia ,Original Article ,AcademicSubjects/MED00310 ,Brainstem ,business ,030217 neurology & neurosurgery - Abstract
Spinocerebellar ataxia type 1 is a progressive neurodegenerative, movement disorder. With potential therapies on the horizon, it is critical to identify biomarkers that (i) differentiate between unaffected and spinocerebellar ataxia Type 1-affected individuals; (ii) track disease progression; and (iii) are directly related to clinical changes of the patient. Magnetic resonance imaging of volumetric changes in the brain may be a suitable source of biomarkers for spinocerebellar ataxia Type 1. In a previous report on a longitudinal study of patients with spinocerebellar ataxia Type 1, we evaluated the volume and magnetic resonance spectroscopy measures of the cerebellum and pons, showing pontine volume and pontine N-acetylaspartate-to-myo-inositol ratio were sensitive to change over time. As a follow-up, the current study conducts a whole brain exploration of volumetric MRI measures with the aim to identify biomarkers for spinocerebellar ataxia Type 1 progression. We adapted a joint label fusion approach using multiple, automatically generated, morphologically matched atlases to label brain regions including cerebellar sub-regions. We adjusted regional volumes by total intracranial volume allowing for linear and power-law relationships. We then utilized Bonferroni corrected linear mixed effects models to (i) determine group differences in regional brain volume and (ii) identify change within affected patients only. We then evaluated the rate of change within each brain region to identify areas that changed most rapidly. Lastly, we used a penalized, linear mixed effects model to determine the strongest brain predictors of motor outcomes. Decrease in pontine volume and accelerating decrease in putamen volume: (i) reliably differentiated spinocerebellar ataxia Type 1-affected and -unaffected individuals; (ii) were observable in affected individuals without referencing an unaffected comparison group; (iii) were detectable within ∼6–9 months; and (iv) were associated with increased disease burden. In conclusion, volumetric change in the pons and putamen may provide powerful biomarkers to track disease progression in spinocerebellar ataxia Type 1. The methods employed here are readily translatable to current clinical settings, providing a framework for study and usage of volumetric neuroimaging biomarkers for clinical trials., There is an urgent need for biomarkers that track neurodegenerative disease progression. Pontine and putamen volume decreases are specific to affected individuals, track disease progression within 6–9 months and are directly related to clinical changes in individuals affected by spinocerebellar ataxia Type 1, making them potential biomarkers for clinical trials., Graphical Abstract
- Published
- 2020
46. Author Correction: A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
- Author
-
Caroline Moreau, James A. Duce, Patrick Gelé, Véronique Danel-Brunaud, Markus Otto, Hélène Blasco, David Devos, Charlotte Veyrat-Durebex, Patrick Oeckl, Timothée Lenglet, Anne Sophie Rolland, Jean-Christophe Devedjian, Mary Dutheil, Peter Bede, Andreas Jeromin, Maeva Kyheng, Guillaume Garçon, Pierre-François Pradat, Vincent Meininger, and Philippe Corcia
- Subjects
Oncology ,medicine.medical_specialty ,Multidisciplinary ,business.industry ,Ferroptosis ,lcsh:R ,lcsh:Medicine ,medicine.disease ,Internal medicine ,medicine ,lcsh:Q ,Amyotrophic lateral sclerosis ,lcsh:Science ,business ,Motor neurone disease - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
47. Estimating risk factors for three negative outcomes in pregnant women admitted to the Centre de Références et Urgences Obstétricales (CRUO) and their neonates in Port-au-Prince, Haiti between January 2013 and June 2018
- Author
-
Reynaldo Grandpierre, Annick Lenglet, Rodnie Senat-Delva, Fedner Desauguste, Emily Borgundvaag, Colette Badjo, Cono Ariti, Michiel Lekkerkerker, Pasquale Finaldi, Gerald Lerebours, and Jorien Schuurmans
- Subjects
medicine.medical_specialty ,Port au prince ,business.industry ,Obstetrics ,Medicine ,business ,female genital diseases and pregnancy complications ,reproductive and urinary physiology - Abstract
Background The prevalence of (pre-)eclampsia in pregnant women in Haiti is high and access to maternal health services is scarce. Limited evidence exists around negative maternal and neonatal outcomes in Haitian women and their offspring. We describe the patient profile of women admitted to an obstetric emergency hospital in Port-au-Prince between January 2013 and June 2018 and the estimated risk factors for maternal death, stillbirth and low birthweight (LBW). Methods We calculated frequencies of age groups, singleton vs. multiple pregnancies, delivery procedures and antenatal care (ANC) services for all maternal admissions. We estimated the associated risk between these factors and the three negative outcomes by calculating odds ratios (OR) and their 95% confidence intervals (CI) using univariate and multivariate logistic regression. We adjusted for an interaction between delivery procedure and pregnancy category in the regression models for maternal death and stillbirth. Results We included 31,509 women and 24,983 deliveries and documented 204 (0.6%) maternal deaths (648/100,000 women giving birth), 1,962 (7.9%) stillbirths and 11,008 (44.1%) LBW neonates. 34.9% of all admissions (n = 10,991) were women with (pre-)eclampsia. Maternal death was more likely in women with complicated pregnancies and/or deliveries and women with (pre-)eclampsia when undergoing a C-section compared to women with uncomplicated vaginal deliveries (OR 4.8; CI 1.7–13.8 and OR 2.3; CI 1.5–3.6 respectively). Stillbirth was more likely in women ≥ 35 years compared to women 20–34 years in complicated pregnancies and/or deliveries (OR 1.3; CI 1.1–1.6) and (pre-)eclampsia (OR 1.4; CI 1.2–1.7). C-sections in women with a complicated pregnancy and/or delivery and women with (pre-)eclampsia reduced the risk of stillbirth (OR 0.7; CI 0.6–0.9 and OR 0.3; CI 0.2–0.3 respectively). Not attending ANC was associated with a higher risk of stillbirth (OR 4.8; CI 3.6–6.6) and LBW (OR 1.4; CI 1.1–1.9) for women with complicated pregnancies and/or deliveries. Conclusion Maternal mortality in high-risk pregnancies in CRUO is higher than the national estimate of 529 per 100,000 deliveries. Attendance of ANC services is associated with a decrease in adverse neonatal outcomes including LBW and stillbirth. We recommend that access to maternal and neonatal healthcare facilities in Port-au-Prince is improved.
- Published
- 2020
- Full Text
- View/download PDF
48. Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations Authors
- Author
-
Florence Cormier, Timothée Lenglet, Alexis Brice, Jean-Christophe Corvol, Fabienne Clot, Vincent Deramecourt, Karl Mondon, Dario Saracino, Stéphane Thobois, Vincent Huin, Aurélie Méneret, Emilie Beaufils, Cécile Delorme, Audrey Gabelle, Fábio Carneiro, Marie Vidailhet, Isabelle Le Ber, Mélissa Tir, Marie-Odile Habert, Daniela Andriuta, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Algorithms, models and methods for images and signals of the human brain (ARAMIS), Sorbonne Université (SU)-Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), UF Neurométabolique Bioclinique et Génétique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 (CNC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Département de neurologie [Montpellier], Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Tours (UT), Service de neurologie [Amiens], CHU Amiens-Picardie, Excellence Laboratory LabEx DISTALZ, The research leading to these results received funding from the 'Investissements d'avenir' ANR-11-INBS-0011. This work was funded by the Programme Hospitalier de Recherche Clinique (PHRC) FTLD-exome (to ILB, promotion by Assistance Publique – Hôpitaux de Paris) and by PHRC Predict-PGRN (to ILB, promotion by Assistance Publique – Hôpitaux de Paris)., Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Lille Neurosciences & Cognition - U 1172 (LilNCog), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 (ISC-MJ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), ANR-16-IDEX-0006,MUSE,MUSE(2016), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Gestionnaire, HAL Sorbonne Université 5, Service de neurologie 1 [CHU Pitié-Salpétrière], Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Tours
- Subjects
Male ,0301 basic medicine ,Parkinson's disease ,TDP-43 ,Disease ,Bioinformatics ,Progranulins ,0302 clinical medicine ,C9orf72 ,Age of Onset ,Family history ,PSP ,Parkinsonism ,Parkinson Disease ,FTD ,Middle Aged ,Pedigree ,3. Good health ,Neurology ,Frontotemporal Dementia ,Neurons and Cognition (q-bio.NC) ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,FTLD ,GRN ,Frontotemporal dementia ,CBS ,03 medical and health sciences ,Parkinsonian Disorders ,medicine ,Humans ,Dementia ,Cognitive Dysfunction ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Aged ,C9orf72 Protein ,business.industry ,medicine.disease ,nervous system diseases ,030104 developmental biology ,Quantitative Biology - Neurons and Cognition ,FOS: Biological sciences ,Mutation ,Etiology ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,030217 neurology & neurosurgery - Abstract
Introduction A phenotype of isolated parkinsonism mimicking Idiopathic Parkinson's Disease (IPD) is a rare clinical presentation of GRN and C9orf72 mutations, the major genetic causes of frontotemporal dementia (FTD). It still remains controversial if this association is fortuitous or not, and which clinical clues could reliably suggest a genetic FTD etiology in IPD patients. This study aims to describe the clinical characteristics of FTD mutation carriers presenting with IPD phenotype, provide neuropathological evidence of the mutation's causality, and specifically address their “red flags” according to current IPD criteria. Methods Seven GRN and C9orf72 carriers with isolated parkinsonism at onset, and three patients from the literature were included in this study. To allow better delineation of their phenotype, the presence of supportive, exclusion and “red flag” features from MDS criteria were analyzed for each case. Results Amongst the ten patients (5 GRN, 5 C9orf72), seven fulfilled probable IPD criteria during all the disease course, while behavioral/language or motoneuron dysfunctions occurred later in three. Disease duration was longer and dopa-responsiveness was more sustained in C9orf72 than in GRN carriers. Subtle motor features, cognitive/behavioral changes, family history of dementia/ALS were suggestive clues for a genetic diagnosis. Importantly, neuropathological examination in one patient revealed typical TDP-43-inclusions without alpha-synucleinopathy, thus demonstrating the causal link between FTD mutations, TDP-43-pathology and PD phenotype. Conclusion We showed that, altogether, family history of early-onset dementia/ALS, the presence of cognitive/behavioral dysfunction and subtle motor characteristics are atypical features frequently present in the parkinsonian presentations of GRN and C9orf72 mutations.
- Published
- 2020
- Full Text
- View/download PDF
49. Robustness of Brain Structural Networks Is Affected in Cognitively Impaired MS Patients
- Author
-
Hamza Farooq, Flavia Nelson, and Christophe Lenglet
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Audiology ,multiple sclerosis ,lcsh:RC346-429 ,diffusion MRI ,03 medical and health sciences ,0302 clinical medicine ,Robustness (computer science) ,imaging bio-markers ,medicine ,Cognitive impairment ,lcsh:Neurology. Diseases of the nervous system ,cognitive impairment ,Expanded Disability Status Scale ,business.industry ,Multiple sclerosis ,Ollivier-Ricci curvature ,Cognition ,Brief Research Report ,medicine.disease ,brain networks ,030104 developmental biology ,brain networks robustness ,Neurology ,Cognitively impaired ,Neurology (clinical) ,Centrality ,business ,030217 neurology & neurosurgery ,Diffusion MRI - Abstract
The robustness of brain structural networks, estimated from diffusion MRI data, may be relevant to cognition. We investigate whether measures of network robustness, such as Ollivier-Ricci curvature, can explain cognitive impairment in multiple sclerosis (MS). We assessed whether local (i.e., cortical area) and/or global (i.e., whole brain) robustness, differs between cognitively impaired (MSCI) and non-impaired (MSNI) MS patients. Fifty patients, with Expanded Disability Status Scale mean (m): 3.2, disease duration m: 12 years, and age m: 40 years, were enrolled. Cognitive impairment scores were estimated from the Minimal Assessment of Cognitive Function in Multiple Sclerosis. Images were obtained in a 3T MRI using a diffusion protocol with a 2 min acquisition time. Brain structural networks were created using 333 cortical areas. Local and global robustness was estimated for each individual, and comparisons were performed between MSCI and MSNI patients. 31 MSCI and 10 MSNI patients were included in the analyses. Brain structural network robustness and centrality showed significant correlations with cognitive impairment. Measures of network robustness and centrality identified specific cortical areas relevant to MS-related cognitive impairment. These measures can be obtained on clinical scanners and are succinct yet accurate potential biomarkers of cognitive impairment.
- Published
- 2020
- Full Text
- View/download PDF
50. Confirmed cases of Neuroborreliosis with involvement of peripheral nervous system: Description of a cohort
- Author
-
Dimitri Psimaras, Thierry Maisonobe, Timothée Lenglet, Karine Viala, Rabab Debs, and Anne-Laure Kaminsky
- Subjects
Male ,neuroborreliosis ,medicine.medical_specialty ,Neuromuscular disease ,Nerve root ,axonal neuropathy ,Axonal loss ,Observational Study ,mononeuritis multiplex ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,peripheral nervous system ,medicine ,Humans ,Lyme Neuroborreliosis ,030212 general & internal medicine ,Peripheral Nerves ,Aged ,Retrospective Studies ,Aged, 80 and over ,electrophysiological study ,Nerve biopsy ,medicine.diagnostic_test ,Mononeuritis Multiplex ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Dermatology ,demyelinating neuropathy ,medicine.anatomical_structure ,meningoradiculoneuritis ,030220 oncology & carcinogenesis ,Peripheral nervous system ,Female ,France ,business ,Neuroborreliosis ,Meningitis ,Research Article - Abstract
The manifestations of borreliosis in the peripheral nervous system (PNS) remain poorly described. As the symptoms of neuroborreliosis can be reversed with timely introduction of antibiotics, early identification could avoid unnecessary axonal loss. Our aim was to describe the characteristics of confirmed neuroborreliosis cases involving the PNS diagnosed between 2007 and 2017 in our neuromuscular disease center in a nonendemic area (La Pitié-Salpêtrière Hospital, Paris, France). Neuroborreliosis was defined as follows: compatible neurological symptoms without other cause of neuropathy; cerebrospinal fluid and serum analysis (positive serological tests with ELISA, confirmed by Western Blot); and improvement of symptoms with adapted antibiotherapy. All the patients consulting in our center between 2007 and 2017 underwent electrophysiological study. Sixteen confirmed cases of neuroborreliosis involving the PNS were included: 10 cases of meningoradiculoneuritis, 4 of axonal neuropathy, and 2 of demyelinating neuropathy (one acute and one chronic). Only 4 (25%) patients reported tick bites. Meningoradiculoneuritis was characterized by lymphocytic meningitis, intense pain, cranial nerve palsy, and contrast enhancement of nerve roots on imagery. The patients with axonal neuropathy presented sensory symptoms with intense pain but no motor deficit and meningitis was rare. Nerve biopsy of 1 patient revealed lymphocytic vasculitis. Electrophysiological testing showed sensory or sensorimotor axonal neuropathy (3 subacute and 1 chronic) of the lower limbs, with asymmetrical neuropathy in 1 patients, symmetrical neuropathy in one and monomelic sensory mononeuritis multiplex in another. We also found 1 case of acute demyelinating neuropathy, treated with antibiotherapy and immunoglobulins, and 1 chronic demyelinating neuropathy. Overall, diaphragmatic paralysis was frequent (18.6%). Antibiotherapy (mostly ceftriaxone 3–4 weeks) resulted in symptom resolution. This series gives an updated overview of the peripheral complications of neuroborreliosis to help identify this disease so that timely treatment could avoid axonal loss.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.